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(A)	WILD-TYPE	 RIBOSOMES	 OF	M.	 SMEGMATIS.	 (B)	HUMAN	 CYTOPLASMIC	 RIBOSOMES.	 (C)	










FIGURE	 18.	 STRUCTURE	 OF	 4’,6’-O-ALKYLDIENE	 (24),	 4’-O-ALKYL	 (25)	 AND	 BICYCLIC	 RING	 I	























































































































































Unfortunately,	 in	 recent	 years	 the	 pace	 of	 developing	 new	 antibiotics	 is	 not	
increasing,	 but	 decreasing	 (Figure	 1).	 Bacterial	 metabolism	 pathways	 provide	 only	 a	
few	 suitable	 targets	 for	 drugs;	 so	 that	 only	 two	 new	 classes	 of	 antibiotics	 have	 been	
developed	 since	 the	 1970s.5-6	 Because	 of	 marketing	 risks,	 big	 pharmaceutical	
companies	have	mostly	cut	off	their	investment	in	developing	new	antibacterial	agents.	
A	report	written	by	the	Infectious	Diseases	Society	of	America	(IDSA)	in	2013	pointed	















































effective	drug	against	 tuberculosis;	 and	 it	 is	 still	 in	use	 today.14	Compared	with	other	
types	 of	 antibiotics,	 AGAs	 are	 attractive	 to	 our	 lab	 for	 several	 advantages.	 They	 are	
considered	 as	 highly	 potent	 broad-spectrum	 antibacterial	 agents	 and	 have	 been	 used	
against	 Gram-negative	 bacteria,	 methicillin-resistant	 Staphylococcus	 aureus	 (MRSA),	
multidrug-resistant	 tuberculosis,	 and	many	 other	 complex	 infectious	 diseases.	 Unlike	
penicillin	 type	 or	 sulfonamide	 type	 antibiotics,	 which	 usually	 cause	 severe	 allergic	
problems,	 aminoglycosides	 lack	 drug-related	 allergic	 effect	 and	 have	 little	 impact	 on	












Aminoglycosides	 are	 hydrophilic	 pseudo-oligosaccharides	 that	 have	 a	 core	
structure	 called	 the	 2-deoxystreptamine	 (2-DOS)	 ring	 (Figure	 4).21	 Amino	 sugars	 are	
linked	 to	 this	 2-DOS	 ring	 by	 glycosidic	 bonds	 to	 generate	 different	 types	 of	
aminoglycosides.21	Most	 of	 the	 clinically	 used	 AGAs	 have	 a	 di-substituted	 2-DOS	 ring	
and	can	be	classified	 into	 two	series	based	on	 the	positions	of	 the	glycosidic	 linkages.	
One	class	is	named	as	4,6-aminoglycosides,	and	includes	kanamycin	2,	gentamicin	3	and	
amikacin	 4,	 in	 which	 the	 2-DOS	 ring	 (ring	 II)	 is	 di-substituted	 in	 positions	 4	 and	 6.	




























Some	 other	 AGAs	 have	 unique	 structures	 and	 do	 no	 fit	 in	 the	 normal	
classification.	Streptomycin	1,	 the	 first	discovered	AGA,	has	a	streptamine	core	 that	 is	
mono-substituted,	 where	 the	 amino	 groups	 have	 been	modified	 to	 guanidino	 groups	




good	 candidate	 for	 the	 next	 generation	 of	 AGAs	 that	 are	 active	 against	 multidrug	
resistant	 bacteria.	 Hygromycin	 B	 9	 (5-substituted-2-deoxystrepaamine	 ring)25	 and	













































       paromomycin (6)
       ribostamycin (7)
4,6-AGA series
e.g: kanamycin (2)
       gentamicin (3)










































































tuberculosis	 showed	 that	 the	 production	 of	 labeled	 protein	 by	 cell-free	 extracts	 was	
blocked,	which	suggested	that	AGAs	inhibit	protein	synthesis.28	After	decades	of	intense	








are	 protonated.	 This	 phenomenon	 provides	 a	 nonspecific	 electrostatic	 interaction	
between	 the	 positively	 charged	 AGAs	 and	 negatively	 charged	 biomolecules,	 including	
lipopolysaccharides	 in	 the	 outer	 bacterial	 membrane	 (Figure	 6).31-32	 The	
energy-dependent	phase	I	is	the	uptake	step	after	AGAs	interact	with	LPS,	which	helps	
transport	AGAs	from	the	outer	membrane	to	the	cytosol	(Figure	6).	The	rate	of	uptake	is	
AGA	 concentration	 dependent,	 and	 can	 be	 interfered	 by	 inhibition	 of	 oxidative	

















peptides	 from	 the	 polypeptide	 chains	 that	 synthesized	 in	 translation	 stage.	 These	
polypeptides	 fold	 to	 secondary	 and	 tertiary	 structure	 to	 generate	 fully	 functionalize	







During	 translation,	 mRNA	 binds	 to	 the	 smaller	 ribosomal	 subunit	 and	 then	
recognizes	the	aminoacyl	transfer	RNA	(tRNA)	that	carries	the	specific	amino	acid.	The	
large	 ribosomal	 subunit	 binds	 to	 form	 an	 initiation	 complex	 and	 starts	 elongate	 the	
polypeptide	chain	by	covalent	attaching	amino	acids.	The	structure	of	mRNA	and	tRNA	
ensures	 the	 accuracy	 of	 translation.	 Ribonucleic	 acid	 consists	 of	 three	 parts:	 the	
phosphate	 backbone,	 the	 ribose	 sugar	 and	 nitrogenous	 bases.	 There	 are	 four	 bases	
found	in	RNA:	adenine	(A),	guanine	(G)	cytosine	(C)	and	uracil	(U).	A	and	G	belong	the	
to	 purine	 bases	 while	 C	 and	 U	 are	 pyrimidine	 bases	 (Figure	 8).	 Watson	 and	 Crick	
discovered	that	those	bases	form	specific	pairs	through	unique	hydrogen	bonds	based	
on	 their	 structure	 in	 1953.	 This	 is	 called	 the	 Watson-Crick	 rule,	 according	 to	 which	
adenine	pairs	with	uracil	by	two	hydrogen	bonds,	while	guanine	pairs	with	cytosine	by	
three	 hydrogen	 bonds	 (Figure	 8).	 A	 specific	 mRNA	 bears	 sequences	 of	 nucleobases	
called	 codons,	 which	 determine	 the	 polypeptide	 that	 needs	 to	 be	 synthesized.	 tRNA	
bears	 complimentary	 nucleobases	 called	 anticodons.	 By	 the	 specific	 codon/anticodon	









per	 codon,33	 implies	 that	beside	codon/anticodon	recognition,	 ribosomes	also	play	an	
important	 role	 in	 securing	 translation	 accuracy.	 The	 ribosome	 contains	 three	 RNA	
binding	 sites:	 (i)	 aminoacyl-tRNA	binding	 site	 (A-site),	 (ii)	 peptidyl	 tRNA	binding	 site	
(P-site)	and	(iii)	empty	tRNA	binding	site	(E-site)	(Figure	9).34	The	A-site	recognizes	and	









electrostatic	 interactions	with	 the	negatively	charged	nucleotides.	 In	 the	 late	1980s,	 it	
was	discovered	that	aminoglycosides	bind	to	the	16S	rRNA	subunit	of	the	30S	bacterial	
ribosome	(Figure	10a).36	This	 is	a	conserved	 loop	that	belongs	 to	 the	small	 ribosomal	
subunit’s	 A-site.37	 AGAs	 can	 selectivity	 bind	 to	 this	 ribosomal	 A-site	 by	 specific	
hydrogen	 bonding	 interactions.	 For	 example,	 the	 ring	 I	 oxygen	 (O5’)	 and	 the	
6’-substituents	 (OH	 in	 paromomycin	 6	 and	 NH2	 in	 neomycin	 5)	 of	 4,5-AGAs	 form	
hydrogen	 bonds	 with	 N-1	 and	 N-6	 of	 A1408	 and	 make	 a	 pseudo	 base-pair	 type	
interaction	(Figure	10b).37-40	There	is	also	a	CH-π	interaction	between	the	β-face	of	ring	


















includes	 other	 conformational	 changes	 occurs	 after	 the	 ‘flipped-out’	 conformation	
forms.	It	 leads	to	tight	binding	of	tRNA	to	the	A-site.45	The	interactions	between	AGAs	








proteins	 as	 mRNA	 is	 misread	 and	 incorrect	 amino	 acid	 is	 incorporated.43-44,	 48	 In	
addition,	the	binding	affinity	of	tRNA	for	the	A-site	is	increased	due	to	the	‘flipped-out’	
conformation	being	locked	up.	This	results	in	stabilization	of	the	pre-translocation	state	












the	 inner	membrane	of	bacteria	and	destabilizing	 it.51-52	Another	 theory	suggests	 that	




such	 as	 Pseudomonas,	 Acinetobacter,	 and	 Enterobacter.	 But	 severe	 toxicity	 problems,	





is	 classified	 as	 nonoliguric	 renal	 failure,	 with	 a	 slow	 rise	 in	 serum	 creatinine	 and	 a	
hypoosmolar	urinary	output.57	During	the	process	of	AGA	excretion,	approximately	5%	
(small	 but	 not	 negligible)	 of	 the	 administered	 dose	 is	 retained	 in	 the	 epithelial	 cells	
lining	 the	 S1	 and	 S2	 segments	 of	 the	 proximal	 tubules58	 after	 glomerular	 filtration.59	
AGAs	bind	to	the	acidic	phospholipids	on	the	brush-border	cell	membrane	due	to	their	
cationic	 form	 under	 physiological	 condition,60	 and	 then	 are	 transferred	 to	 the	
transmembrane	protein	megalin,	with	which	they	become	internalized	in	endosomes.61	
Once	passing	through	cell	membranes,	the	accumulated	AGAs	are	mainly	localized	with	







and	 kidney	 failure	 if	 untreated.17	 Several	 strategies	 have	 been	 developed	 to	 reduce	
nephrotoxicity,	 of	 which	 the	 most	 common	 method	 used	 in	 the	 clinic	 is	 the	
administration	 of	 a	 single	 large	 daily	 dose	 instead	 of	 separate	 smaller	 doses	 or	
continuous	infusion.66	The	logic	behind	this	strategy	is	that	the	large	excess	of	drug	can	
be	excreted	without	causing	toxicity	as	the	uptake	of	AGAs	by	renal	cells	is	saturated	at	
relatively	 low	 concentrations.57,	 67	 At	 the	 same	 time	 the	 large	 dose	 is	 lethal	 to	 the	
bacterial	 infection.	 Another	 useful	 strategy	 is	 to	 decrease	 the	 binding	 of	 AGAs	 with	
lysosomal	 phospholipids,	 either	 by	 modification	 of	 AGAs	 (i.e.	 by	 acylation	 of	
N-1-position,	 as	 in	 amikacin	 4)68	 or	 by	 co-administration	 of	 other	 drugs	 that	 can	
competitively	 bind	 to	 the	 phospholipids	 (i.e.	 polyaspartic	 acid).69	 Some	 reports	 also	
show	 that	 hydration	 therapy	 can	 alleviate	 the	 symptoms	 of	 AGA-induced	
nephrotoxicity.17	
1.4.2. Ototoxicity	
Ototoxicity	 is	 another	 important	 and	 severe	 side	 effect	 of	 aminoglycoside	
therapy.	According	 to	 reports,	 nearly	20%	of	patient	populations,	who	undergo	AGAs	
treatment,	suffer	from	irreversible	ototoxicty.70	There	are	two	symptoms	of	ototoxicity,	
including	 imbalance	 disorder	 that	 is	 caused	 by	 damage	 of	 the	 vestibular	 system,	 and	





ototoxic	 potentials.	 Thus,	 neomycin	5,	 a	 representative	 of	 the	 4,5-AGAs,	 is	 known	 as	
more	 ototoxic	 than	 gentamicin	 3	 or	 tobramycin	 11	 (both	 belong	 to	 4,6-AGAs).	
Additionally,	 in	 longer	 therapeutic	 AGAs	 regimes,	 as	 in	 the	 treatment	 of	 tuberculosis,	
kidney	 malfunction,	 and	 nutritional	 and	 physiological	 states	 of	 the	 patients	 also	
contribute	to	the	severity	of	ototoxicity.71	 	
AGAs	disrupt	 sensory	 hair	 cells	 of	 the	 inner	 ear,	 leading	 to	 irreversible	 effects	
because	 once	 damaged,	 such	 cells	 cannot	 be	 regenerated.17,	65,	72	 The	 uptake	 of	 AGAs	
into	 the	 inner	ear	 is	very	 fast	 (a	 few	minutes),	meanwhile	 the	half-life	of	AGAs	 in	 the	
inner	 ear	 can	 reach	 a	month	 (as	 compared	 to	 3-5	h	 in	 the	plasma),	which	makes	 the	






of	 those	 cells,	 cause	 inhibition	 of	 mitochondrial	 protein	 synthesis,	 or	 promotion	 of	
abnormal	 mitochondrial	 protein	 synthesis,	 which	 result	 in	 ROS	 formation	 and	 cell	
apoptosis.77-80	 There	 are	 two	 ways	 that	 ototoxicity	 occurs:	 (i)	 a	 sporadic	






Unlike	 nephrotoxicity,	 there	 is	 still	 no	 practical	 clinical	 regime	 to	 prevent	
AGA-induced	 ototoxicity.	 However,	 antioxidant	 therapy	 shows	 potential	 to	 attenuate	




The	 selectivity	 of	 aminoglycosides	 relies	 on	 the	 small	 sequence	 differences	
between	 the	 ribosome	 A-site	 of	 eukaryotic	 cells	 and	 prokaryotic	 cells.	 At	 the	 1408	
position,	an	adenine	residue	(A)	is	found	in	bacteria,	but	a	guanine	residue	(G)	is	found	
in	 human	 cytoplasmic	 RNA	 (Figure	 14).	 As	 discussed	 in	 the	 previous	 section,	 the	 A	
residue	 provides	 key	 hydrogen	 bond	 interactions	 with	 the	 6’-substituent	 of	




site,	 on	 the	 other	 hand,	 is	 more	 similar	 to	 bacteria	 A-site.	 They	 share	 the	 same	 key	
A1408	residue	(Figure	14),	which	leads	to	lower	selectivity	for	the	bacteria	A-site	over	
the	 mitochondrial	 A-site	 and	 results	 in	 ototoxicity.80	 In	 the	 case	 of	 deafness	 mutant,	





binding	pocket	 and	 increases	 the	binding	 affinity	of	AGAs	 to	 those	mutated	 ribosome	
A-site	(Figure	14).	
Prof.	 Böttger,	 our	 collaborator	 in	 the	 Univeristy	 of	 Zurich,	 has	 developed	 an	
efficient	 genetic	 tool	 to	 study	 the	 interaction	 between	 eukaryotic	 rRNA	 with	
aminoglycosides	 and	 to	 screen	 AGAs	 derivatives	 for	 their	 antibacterial	 activities	 and	
selectivity.	 His	 group	 replaced	 the	 A-site	 of	 16S	 rRNA	 of	 M.	 smegmatis	 with	 its	
eukaryotic	counterpart,	and	obtained	the	purified	70S	hybrid	bacterial	ribosomes	with	
fully	functional	human	cytosolic	A-site	(Cyt	14),	human	mitochondrial	A-site	(Mit	13)	or	
mitochondrial	 A1555G	 A-site	 (deafness	 mutation,	 A1555G).84	 Those	 recombinant	












One	 of	 the	 main	 properties	 of	 next	 generation	 of	 aminoglycosides	 must	 be	
circumvention	 of	 antibiotic	 resistance.	 The	 most	 common	 resistance	 mechanisms	





	 	 	 	 	 	 The	 uptake	 of	 AGAs	 is	 highly	 relying	 on	 the	 interaction	 between	 positively	
charged	 AGA	 molecules	 and	 the	 negatively	 charged	 LPS,	 so	 modifications	 of	 LPS	
diminish	the	AGAs	uptake.	Incorporation	with	4-amino-4-deoxy-L-arabinose	is	the	most	
common	modification	of	LPS,	which	reduces	the	net	negative	charge	of	LPS	and	leads	to	
the	 decrease	 of	 AGAs	 uptake.85-87	 Other	 modifications	 include	 adding	















Aminoglycosides	 are	 produced	 by	 certain	 bacteria	 strains	 (Streptomyces	 and	
Micromonospora).	 In	 order	 to	 protect	 themselves,	 those	 bacteria	 develop	 a	 defensive	
mechanism	 by	 methylation	 of	 their	 16S	 RNA	 A-site	 with	 rRNA	 methylases.93-94	 For	
example,	 M.	 purpurea	 (producer	 of	 gentamicin	 3)	 and	 S.	 tenebrarius	 (producer	 of	
tobramycin	11)	modify	the	G1405	and	A1408	residues	 in	their	ribosome	A-site	to	the	
7-methyl	derivatives.95	This	mechanism	is	not	considered	as	a	threat	until	it	spreads	to	
various	 pathogenic	 bacteria	 recently	 and	 affects	 all	 the	 clinical	 used	 4,6-AGAs	 as	
methylated	G1405	disrupt	 the	key	 interaction	between	the	binding	site	and	ring	 III	of	
that	 series.16,	 96-98	 Common	 examples	 of	 these	 rRNA	 methylases	 include:	 RmtA	 in	 P.	
aeruginosa;99	 RmtB	 in	 S.	 marcescens,	 A.	 baumannii.	 P.	 aeruginosa,	 E.	 coli,	 and	 K.	







aminoglycosides	 and	 inactivate	 the	 drug	 molecule.27,	 36,	 104-106	 They	 are	 the	 most	
widespread	and	clinically	relevant	mechanism	of	AGA-resistance.	There	are	three	major	
categories	 of	 AMEs:	 (i)	 aminoglycoside	 acetyltransferases	 (AACs),	 (ii)	 aminoglycoside	
phosphotransferases	 (APHs),	 and	 (iii)	 aminoglycoside	nucleotidyltransferases	 (ANTs),	
which	 can	 modify	 AGA	 molecules	 by	 acetylating	 the	 free	 amino	 groups	 (AACs)	 or	



































































































been	 identified	 in	 both	 Gram-positive	 and	 Gram-negative	 bacteria.	 They	 belong	 to	
ubiquitous	 GCN5-related	 N-acetyltransferase	 superfamily	 of	 protein.107	 The	 AACs	
catalyze	acetylation	at	the	1	[AAC(1)],	3	[AAC(3)],	2’	[AAC(2’)]	or	6’	[AAC(6’)]	position	of	
AGAs,	 reduce	 the	 positive	 charge	 of	 the	 molecules	 and	 generate	 steric	 hindrance	 to	
block	the	binding.	AAC(1)	enzymes	are	not	the	major	threat	because	they	do	not	cause	
significant	 reduction	 of	 the	 antibacterial	 activity	 and	 are	 rarely	 found	 in	 clinical	
isolates.108-109	There	are	nine	 subclasses	of	AAC(3)	described	 to	date,	which	are	all	 in	
Gram-negative	 bacteria.109	 They	 confer	 resistance	 to	 most	 4,6-AGAs	 including	
gentamicin	3,	tobramycin	11,	sisomicin	14,	fortimicin	15,	dibekacin	16,	and	netilmicin	






	 	 	 	 	 	 APHs	catalyze	the	regiospecific	transfer	of	the	γ-phosphoryl	group	of	the	ATP	to	
the	 hydroxy	 group	 of	 aminoglycosides.	 Phosphorylation	 of	 specific	 hydroxy	 groups	
leads	 to:	 (i)	 reduction	 of	 the	 binding	 affinity	 of	AGAs	by	 introducing	negative	 charge,	








	 	 	 	 	 	 ANTs	 deactivate	 aminoglycosides	 by	 modifying	 hydroxy	 groups	 of	 AGAs	 with	
AMP	group	from	the	donor	substrate	ATP.	This	is	the	smallest	AMEs	family,17	and	only	
five	 classes	 have	 been	 identified	 so	 far	 [ANT(6),	 ANT(9),	 ANT(4’),	 ANT(2’’),	 and	
ANT(3’’)].109	The	most	commonly	found	ANTs	are	ANT(3’’),	but	they	are	not	considered	





or	 biosynthesis	 of	 aminoglycoside	 modifying	 enzymes,109	 and	 modification	 of	
aminoglycoside	 molecules	 to	 make	 them	 resistance-proof.	 In	 order	 to	 inhibit	 the	
activities	 of	 AMEs,	 several	 methods	 have	 been	 studied.	 For	 example,	
aminoglycoside-CoA	 bi-substrates	 can	 inhibit	 AAC(3)	 and	 AAC(6’)	 by	 mimicking	 the	
intermediate	 complex	 or	 random	 binding	 to	 the	 enzymes.116-121	 In	 another	 study,	
cationic	 antimicrobial	 peptides,	 such	 as	 bovine	 peptide	 indolicidin,	 showed	 inhibition	
activities	against	APHs	and	AACs.122	Two	non-carbohydrate	di-amine	derivatives123	and	
some	known	 eukaryotic	 protein	 kinase	 inhibitors124	 are	 also	 active	 against	ANTs	 and	
APHs.	 A	 number	 of	 antisense	 oligonucleotides	 or	 oligonucleotides	 analogs	 have	 been	




deoxyribozymes	 are	 another	 example	 that	 can	 target	 genes	 coding	AMEs	 and	 restore	
susceptibility	of	AGAs.129-130	
Modified	 AGAs	 show	 promising	 results	 in	 defeating	 AGA	 resistant	 bacterial	





have	 six.133	 Neamine	 analogs,	 such	 as	 dimer	 18,134	 semisynthetic	 derivatives	
pyranmycin	19,135	 pyrankacin	20,136	 and	 amikacin	mimetic	21,137	 are	 not	 affected	by	
certain	 AMEs	 [AAC(6’),	 APH(2’),	 and	 APH(3’)]	 and	 are	 active	 against	 AGA	 resistant	
strains.	 Neomycin	 binds	 to	 bacterial	 A-site	 and	 ANT(4’)	 active	 site	 with	 different	
conformation.	So	a	conformationally	locked	up	derivative	of	neomycin	22	was	designed,	
synthesized	and	tested,	and	showed	no	binding	affinity	to	ANT(4’)	and	AAC(2’).138	AGA	
hybrid	23	 that	 contains	 ring	 I	 of	 sisomicin	14	 and	 ring	 II,	 III,	 and	 IV	 of	 neomycin	5	









	 	 	 	 	 	 Increasing	 the	 efflux	 of	 the	 drug	 molecules	 is	 an	 additional	 mechanism	 of	
resistance	of	AGAs.	Due	to	the	polycationic	structure	of	aminoglycosides,	efflux	pumps	
are	 needed	 to	 transport	 AGAs	 out	 of	 the	 cell,	 and	 only	 a	 few	 of	 them	 have	 been	
identified.140-141	 AcrAD	 is	 the	main	 AGAs	 efflux	 pump	 in	 Gram-negative	 bacteria	 that	
belongs	 to	 the	resistance-nodulation-division	(RND)-type	 transporter	superfamily	and	
corresponds	 to	 AGAs	 resistance.142	 Besides	 that,	 the	 multidrug	 and	 toxic	 compound	
extrusion	 (MATE)	 efflux	 pumps	 family	 in	 Vibrio	 cholerea	 and	 the	 major	 facilitator	




























































































































































In	 the	 last	 few	 years,	 several	 research	 groups	 have	 begun	 to	 develop	 the	 next	
generation	 of	 aminoglycosides	 antibiotics.	 The	 Crich	 and	 Vasella	 groups	 collaborated	
and	focus	on	modification	of	existing	AGAs.	They	synthesized	a	series	of	4’,6’-position,	
4’-position	and	bicyclic	ring	I	modified	paromomycin	6	analogs,	which	retained	the	full	







in	 animals	 for	 decades,	 and	 recent	 study	 shows	 that	 it	 is	 one	 of	 the	 least	 ototoxic	
aminoglycosides,	probably	due	 to	 the	unique	bicyclic	 core	 structure.150	The	Crich	and	



















































apramycin	by	modifying	 the	6’-	 and	7’-positions.151	Now,	apramycin	 is	expected	 to	go	
into	a	phase	I	clinical	trial	in	Europe.	 	
Plazomicin	27	is	a	semisynthetic	aminoglycoside	that	has	been	developed	by	the	




mechanism.153	 It	 is	 6’-(2-hydroxyethyl)-1-(4-amino-2(S)-hydroxybutyryl)	 sisomicin,152	
in	 which	 the	 6’-modification	 can	 protect	 the	 molecule	 from	 AAC(6’),	 and	 the	





	 	 	 	 	 	 The	 overall	 goal	 of	 this	 thesis	 was	 to	 develop	 the	 next	 generation	 of	
aminoglycosides	 that	 are	 nontoxic	 and	 resistant-proof	 by	 rational	 design	 and	 novel	
organic	 synthesis.	 We	 aimed	 to	 exploit	 the	 known	 structural	 differences	 between	
bacterial	 ribosome	A-site	 and	mitochondrial	 ribosome	A-site	 to	design	more	 selective	






















active	 against	 AGA	 resistant	 bacterial	 strains.	 We	 choose	 to	 modify	 4,5-AGAs	 as	 the	
A-site	G1405	methylation	resistance	mechanism	mentioned	in	previous	chapter	affects	
all	 4,6-AGAs.	Paromomycin	6,	 compared	with	neomycin	5,	 is	 less	 toxic	because	 it	 has	
less	 free	 amine	 groups,	 which	 makes	 it	 good	 substrate	 for	 modifications.	 Several	
modifications,	 including	 single	 modification	 at	 the	 6’	 and	 3’	 positions,	 double	
modification	at	the	3’,5’’	positions,	and	triple	modification	at	the	3’,	4’,	5’’	positions	were	







The	 6’-position	 of	 aminoglycosides	 is	 crucial	 for	 AGA	 binding	 to	 the	 ribosome	
A-site.	As	discussed	in	the	previous	chapter,	the	6’-substituents	(OH	or	NH2)	and	ring	I	
oxygen	 (O5’)	 form	 hydrogen	 bonds	 with	 N-1	 and	 N-6	 of	 the	 A1408	 residue	 in	 the	
bacterial	ribosome	A-site,	making	a	pseudo	base-pair	type	interaction	between	16S	RNA	
and	the	drug	molecule.37-40	The	importance	of	the	6’-position	makes	it	a	good	target	for	
resistance	mechanisms.	 AAC(6’),	 one	 of	 the	most	 common	 aminoglycoside	modifying	
enzymes,	can	catalyze	acetylation	at	 the	6’-position	using	acetyl	coenzyme	A	as	donor	
substrate,109	and	deactivate	AGAs	that	have	a	6’-amino	group.	The	16S	Ribosomal	RNA	
methyltransferases	 (RMTases),	 which	 some	 bacteria	 use	 to	 protect	 themselves	 from	
aminoglycoside	 action,	 are	 another	 resistance	 mechanism	 that	 can	 involve	 the	
6’-position.	NpmA,	a	RMTase	that	methylates	the	N-1	position	of	A1408,	has	low	clinical	
prevalence,	but	 is	a	considerable	potential	 threat	because	 it	affects	not	only	4,6-AGAs,	
but	 also	 4,5-AGAs.109	 The	 methylated	 A1408	 residue	 loses	 the	 ability	 to	 form	 the	
important	 pseudo	 base-pair	 hydrogen	 bond	 interaction	 and	 also	 sterically	 blocks	 the	
binding	pocket	of	ring	I.	 	
Some	modifications	have	been	made	at	the	6’-position	of	paromomycin	6	in	the	
Crich	 laboratory.	 6’-Deoxy	 paromomycin	 28	 and	 6’-deoxy-6’-fluoro	 paromomycin	 29	





do	 more	 modifications	 at	 this	 position	 of	 paromomycin	 6.149	 These	 existing	









The	 synthesis	 of	 6’-deshydroxymethyl	 paromomycin	30	 started	 from	 the	 fully	
protected	paromomycin	 intermediate	31,154	whose	 selective	 reduction	was	needed	 to	
afford	the	free	6’-monohydroxy	intermediate	32.	Several	different	conditions,	including	
borane	 trimethylamine	 with	 dibutylboron	 triflate;	 borane	 tetrahydrofuran	 complex	
with	copper(II)	 triflate;155	and	borane	dimethyl	sulfide	with	copper(II)	 triflate,155	were	
tried	in	an	attempt	to	optimize	selectivity	and	obtain	a	good	yield.	The	best	conditions	
we	 found	 were	 borane	 dimethyl	 sulfide	 (2	 M	 solution	 in	 tetrahydrofuran)	 and	
dibutylboron	triflate	(1	M	solution	in	dichloromethane),147	which	gave	compound	32	in	




















































bleach156	 to	 the	 uronic	 acid	 33	 in	 79%	 yield.	 Barton’s	 decarboxylation	 reaction	 was	
utilized	 to	remove	 the	5’-carboxylic	acid.157	The	reaction	was	carried	out	under	white	
light	 photolysis	 conditions	 with	 tert-dodecanethiol	 as	 hydrogen	 atom	 source,158	 and	
gave	 the	 fully	 protected	 6’-deshydroxymethyl	 derivative	 34	 in	 55%	 yield.	 A	
photocatalytic	 decarboxylation	 method	 developed	 by	 Macmillan159-160	 was	 also	
examined	for	comparison	purposes.	The	results	showed	that	Barton’s	decarboxylation	













The	 above	 synthesized	 paromomycin	 derivative	 30	 was	 tested	 for	 ribosomal	
activity	 and	 antibacterial	 activity	 by	 the	 Böttger	 group	 in	 Zurich,	 together	 with	 the	
parent	molecule	paromomycin	6	and	6’-deoxy	paromomycin	28.	The	ribosomal	activity	
is	 obtained	 from	 the	 IC50	 values	 of	 functional	 cell-free	 ribosomal	 assays	 with	 the	
different	 ribosomes	 as	 discussed	 in	 the	 previous	 chapter.	 Four	 different	 70S	 purified	
ribosomes	 that	 carry	 the	 rRNA	binding	A-site,	 including	 the	wild-type	bacterial	A-site	
(Bacterial),	the	human	cytosolic	A-site	(Cyt14),	the	human	mitochondrial	A-site	(Mit13),	
and	the	deafness	mutation	A-site	(A1555G),	were	screened,79,	84	and	the	data	are	shown	
2M BH3Me2S in THF, 









































































































noticeable	 decrease	 in	 selectivity	 as	 the	 reduction	 of	 activity	 toward	 all	 three	 hybrid	







Mit13	 Sel.	 A1555G	 Sel.	 Cyt14	 Sel.	
Paromomycin	6	 0.03	 50.6	 1688	 5.5	 184	 10.6	 353	
6’-Deoxy	
paromomycin	28	
0.09	 166.2	 1846	 93.2	 1036	 152.1	 1690	
6’-Deshydroxymethyl	
paromomycin	30	
0.23	 89.4	 389	 38.0	 165	 42.9	 186	
Similar	 trends	 also	 appeared	 in	 the	 antibacterial	 activity	 (Table	 2).	 The	
























































































The	 removal	 of	 hydrophobic	 6’-methyl	 group	 of	 6’-deoxy	 paromomycin	 28	
cannot	be	considered	as	an	effective	modification.	The	lost	of	antiribosomal	activity	and	
selectivity	 suggested	 that	 even	 without	 the	 critical	 hydroxy	 group	 (hydrogen	 bond	





decrease	 of	 activity.	 Another	 possible	 explanation	would	 be	 that	 the	 6’-methyl	 group	
therefore	 provides	 a	 certain	 hydrophobic	 interaction	 to	 stabilize	 the	 binding.	 The	
disappearance	 of	 this	 hydrophobic	 group	 of	 compound	 30	 results	 in	 loss	 of	 this	
stabilization	 and	 decreased	 binding	 affinity.	 However,	 compound	 30	 was	 not	
















class	of	APH(3’)	 shows	a	 resistance	profile	 that	 includes	most	4,5-AGAs	 (neomycin	5,	
paromomycin	6,	ribostamycin	7	and	lividomycin	A	35)	and	some	4,6-AGAs	(kanamycin	
2).109	 The	 APH(3’)-II	 subclass	 also	 has	 three	 isozymes	 (APH(3’)-IIa,	 APH(3’)-IIb	 and	
APH(3’)-IIc)	and	targets	kanamycin	2,	neomycin	5,	paromomycin	6,	ribostamycin	7	and	
butirosin	36.109	 APH(3’)-IIa	 is	 well	 studied	 and	 its	 crystal	 structure	 in	 complex	 with	
kanamycin	2	 has	 been	 resolved.162	 The	 epidemiological	 data	 of	APH(3’)-IIIa	 has	 been	
extensively	 reviewed.162	 It	 is	 highly	 disseminated	 within	 Gram-positive	 bacteria	 and	
deactivates	 kanamycin	 2,	 amikacin	 4,	 neomycin	 5,	 paromomycin	 6,	 isepamicin	 13,	
lividomycin	 A	 35	 and	 butirosin	 36	 (Figure	 21).109	 This	 enzyme	 also	 shows	 APH(5’’)	


























































Since	 APH(3’)s	 are	 widely	 distributed	 and	 their	 resistance	 spectra	 are	 large,	
strategies	 that	 can	 fight	 against	 this	 resistance	 mechanism	 are	 desperately	 needed.	
Modifying	 the	 3’-position	 to	 remove	 the	 hydroxy	 group	 that	 is	 susceptible	 to	 the	
enzymes	 has	 been	 proved	 to	 be	 effective.	 Gentamicin	 3	 and	 tobramycin	 11	 are	 two	
examples	 of	 clinically	 used	 3’-deoxy	 aminoglycosides	 that	 are	 active	 against	 bacterial	
strains	 with	 the	 APH(3’)	 resistance	 mechanism.	 Although	 some	 3’-deoxy	 AGAs	 are	
cheaply	 available	 in	 large	 scale	 by	 fermentation,	 chemical	 approaches	 to	 achieve	
3’-deoxygenation	modification	on	aminoglycosides	have	been	studied	 in	order	 to	gain	
more	knowledge	about	how	 this	modification	 can	affect	 the	activity	 and	 selectivity	of	
different	 AGAs.	 For	 example,	 3’-deoxy	 kanamycin	 A	37	 can	 be	 synthesized	 through	 a	
glycosylation	reaction	between	the	3’-deoxy	ring	 I	glycosyl	donor	38	and	acceptor	39	
(Scheme	2A).163	Tobramycin	11	has	also	been	prepared	directly	from	kanamycin	2	with	
selective	 functionalization	 at	 the	 3’-position	 (Scheme	 2B).164	 However,	 the	 reported	
methods	 have	 disadvantages	 such	 as	 low	 yields	 for	 the	 key	 reactions,163	 and	 limited	
substrate	 scope.164	 In	 this	 chapter,	 two	 different	 methods	 to	 synthesize	 3’-deoxy	
paromomycin	41	are	discussed,	and	three	different	3’-deoxy	4,5-AGAs	are	synthesized.	








3’-Deoxy	 paromomycin	 41,	 also	 known	 as	 lividomycin	 B,	 was	 prepared	 from	
lividomycin	 A	 35,	 a	 paromomycin	 analog	 that	 contains	 the	 3’-deoxy	 ring	 I	 and	 a	
mannose	 ring	 (ring	 V)	 at	 the	 4’’’	 position,	 by	 a	 slightly	 modified	 procedure	 of	 the	
chemical	 conversion	 reported	by	Mori	 et	 al.	 in	1972.165	The	procedure	comprised	 the	
protection	 of	 lividomycin	A	35,	 followed	by	degradation	 of	 the	mannose	moiety	with	
periodate	and	phenylhydrazine	and	subsequent	de-protection.165	Lividomycin	A	35	was	
reacted	with	 imidazolesulfonyl	 azide	 hydrochloride	 salt	 in	 the	 presence	 of	 potassium	
carbonate	 and	 catalytic	 copper(II)	 sulfate	pentahydrate	 to	 give	 perazide	 intermediate	
42.	The	degradation	of	the	mannose	ring	V	was	accomplished	by	sequential	treatment	
with	 sodium	 periodate,	 ethylene	 glycol,	 lead	 diacetate,	 sulfuric	 acid	 and	
phenylhydrazine	 in	 acetic	 acid	 condition.	 Intermediate	43	was	obtained	 in	10%	yield	














































































v) TsCl, -20 oC
i) NaI













with	 sodium	 periodate	 oxidized	 the	 2’’’’,	 3’’’’-cis-diol	 of	 the	 mannose	 ring	 to	 a	
di-aldehyde	 (i),	 in	 which	 the	 two	 carbonyl	 groups	 were	 temporarily	 protected	 by	
forming	cyclic	acetals	(ii)	with	ethylene	glycol.	After	removal	of	iodate	by	precipitation	
with	 lead	 acetate,	 the	 excess	 lead	 was	 removed	 by	 treatment	 with	 sulfuric	 acid	 and	
filtration.	The	di-aldehyde	 (i)	was	regenerated	by	hydrolyzing	 the	acetals	and	reacted	




























v) AcOH and phenylhydrazine
H2O




























































The	 synthetic	 scheme	 discussed	 in	 previous	 section	 had	 a	 drawback	 as	 the	
starting	 material	 lividomycin	 35	 was	 not	 commercial	 available.	 A	 methodology	 to	
expose	the	3’-position	of	paromamine	44	for	individual	functional	group	transformation	
was	 reported	 in	 2006.166	 Cyclohexanone	 dimethyl	 acetal	 was	 used	 to	 form	
di-cyclohexylidene	 intermediate	 45,	 in	 which	 all	 functional	 groups	 were	 protected	
except	 for	 the	 3’-hydroxy	 group	 (Scheme	 4).166	 However,	 utilizing	 this	 strategy	 on	
synthesize	more	complex	3’-deoxy	aminoglycosides	requires	controlled	degradation	of	
AGA	 to	 paromoamine	44	 and	 re-glycosylation	 after	 the	 3’-modification	 is	 completed,	
















































Samarium	 iodide	 is	 a	 one-electron	 reducing	 reagent	 well	 known	 for	 its	 many	
chemoselective	 reductions.167	 Its	 applications	 include	 reductive	 cleavage	 of	 α-alkoxy	
groups	 from	 α-alkoxy	 ketones	 and	 the	 reduction	 of	 ketones	 to	 corresponding	
alcohols168	(Figure	23).	To	exploit	this	reagent	in	the	synthesis	of	the	targeted	3’-deoxy	
4,5-AGAs,	an	O-selective	oxidation	of	the	4’-hydroxy	group	of	ring	I	of	AGAs	is	necessary.	





The	 synthetic	 scheme	 started	 from	protected	 paromomycin	 derivative	46	 that	
has	been	described	in	the	literature,	in	which	only	the	4’-hydroxy	group	is	exposed.148,	
154	It	has	been	reported	that	azide	groups	can	be	reduced	to	the	corresponding	primary	
amines	 upon	 treatment	with	 excess	 samarium	 iodide,169-170	 so	 changing	 of	 the	 amino	











































direct	 treatment	 with	 N-(benzyloxycarbonyloxy)succinimide	 and	 sodium	 carbonate.	
Alcohol	 47	 was	 obtained	 in	 45%	 yield	 over	 two	 steps	 and	 was	 oxidized	 with	
Dess-Martin	 periodinane	 to	 afford	 the	 corresponding	 ketone	 48	 in	 88%	 yield.	








i) PMe3, THF, 






























































































Some	 interesting	 discoveries	 were	 made	 in	 this	 samarium	 iodide	 reductive	
cleavage	reaction.	The	proposed	mechanism	of	the	reductive	cleavage	of	α-alkoxy	group	
of	ketone	is	shown	in	Figure	24.	This	process	may	be	initiated	by	electron	transfer	from	
samarium	 iodide	 to	 the	 carbonyl	 moiety	 of	 compound	 48	 and	 generates	 samarium	
alkoxide	 radical	 i.	 A	 second	 reduction	 immediately	 follows,	 after	 which	 samarium	
alkoxide	anion	 ii	 is	 formed.	This	anion	can	be	 trapped	by	protonation,	which	 leads	 to	
the	4’-alcohol	47	outlined	in	Scheme	5	(Figure	24,	pathway	A).	Two	possible	elimination	
reactions	 can	 also	 occur,	 as	 the	 3’-	 and	 5’-positions	 are	 both	 at	 the	 α-position	 of	 the	
4’-ketone.	 The	 cleavages	 of	 5’-carbon-oxygen	 bond	 forms	 alcohol	50	 by	 generating	 a	
ring	 I	 opened	 samarium	 alkoxide	 enolate	 type	 intermediate	 iiib,	 which	 rearranges	
rapidly	and	causes	the	degradation	of	ring	I	(Figure	24,	pathway	B).	On	the	other	hand,	
the	cleavage	of	 the	3’-carbon-oxygen	bond	results	 in	de-oxygenation	at	 the	3’-position	
and	 affords	 another	 samarium	 alkoxide	 enolate	 type	 intermediate	 iiic	 (Figure	 24,	
pathway	 C).	 After	 the	 hydrolysis	 of	 the	 samarium-oxygen	 single	 bond,	 enolate	 iv	 is	
formed	 and	 easily	 tautomerizes	 to	 give	 3’-deoxy-4’-keto	 paromomycin	 derivative	51.	
Excess	samarium	iodide	initiates	second	reaction	at	the	4’-ketone,	generates	samarium	








The	 reaction	 was	 conducted	 at	 different	 temperatures	 and	 different	 products	
were	observed.	At	-78	°C,	reaction	proceeded	slowly	and	3’-deoxy-4’-keto	paromomycin	
derivative	 51	 was	 formed	 through	 pathway	 C	 without	 any	 sign	 of	 reduction	 of	 the	
4’-ketone	or	of	decomposition	of	the	ring	I.	It	was	found	that	increasing	the	temperature	
accelerates	 the	 reaction.	 Compared	 with	 stirring	 at	 -78	 °C	 overnight,	 the	 same	
3’-deoxy-4’-keto	product	51	was	obtained	in	good	yield	in	1	h	on	treatment	of	48	with	
samarium	iodide	at	-20	°C.	However,	further	increasing	the	temperature	affects	not	only	
the	 reaction	 rate,	 but	 also	 the	 reaction	mechanism.	 Alcohol	50,	which	was	 generated	
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1	 -78	°C	 1	h	 Starting	material	(48)	 -	
2	 -78	°C	 Overnight	 	 3’-deoxy-4’-keto	product	
(51)	
-	
3	 -20	°C	 1h	 3’-deoxy-4’-keto	product	
(51)	
70%	






of	 the	 3’-	 or	 5’-carbon-oxygen	 bond.	 When	 the	 reaction	 proceeds	 at	 very	 low	
temperature	 (-78	 °C),	 the	 dominant	 conformation	 of	 ring	 I	 is	 the	 stable	 chair	
conformation,	which	provides	no	orbital	overlapping	 (Figure	25,	 left).	 So	 the	 reaction	
progress	 is	 very	 slow	at	 this	 temperature.	As	 the	 reaction	 temperature	 increases,	 the	
chair	 conformation	 is	 able	 to	 convert	 to	 boat	 conformations	 (Figure	25,	 right),	which	
affords	 an	 orbital	 overlapping	 between	 the	 4’-position	 and	 3’-position,	 making	 the	
cleavage	 of	 the	 3’-O-benzyl	 group	 become	 easier	 and	 accelerating	 the	 reaction.	
Meanwhile,	 there	 is	 no	 orbital	 overlapping	 between	 the	 4’	 and	 5’-position	 in	 chair	
conformation	or	boat	conformation.	In	order	to	break	the	5’-carbon-oxygen	bond,	more	
energy	is	required	to	achieve	an	unstable	conformation	that	allows	the	overlap	between	
4’-	 and	 5’-position.	 In	 this	 case,	 when	 the	 reaction	 is	 proceeded	 at	 -20	 °C,	 there	 is	









Having	 identified	 the	 best	 temperature	 to	 operate	 the	 samarium	 iodide	
reduction,	 other	 parameters	 of	 this	 reaction	 were	 optimized	 to	 generate	 the	
3’-deoxy-4’-hydroxy	 paromomycin	 derivative	 49	 in	 one	 pot.	 Based	 on	 the	 proposed	
mechanism,	at	least	four	equivalents	of	samarium	iodide	are	needed	to	achieve	alcohol	
49	 in	 good	 yield.	 An	 extra	 proton	 source	 is	 also	 required	 to	 hydrolyze	 the	 samarium	
alkoxide	intermediate	vii	to	generate	alcohol	49.	Combinations	of	different	amounts	of	































1	 4	 10	 1	h	+	2	h	 Compound	50a	&	51	
2	 6	 10	 1	h	+	2	h	 Compound	49	in	42%	











	 	 	 	 	 	 The	reaction	was	first	conducted	at	-20	°C	for	1	h	to	complete	the	de-oxygenation	
reaction	at	 the	3’-position,	 then	 the	 temperature	was	slightly	 increased	and	methanol	
was	added	so	that	the	carbonyl	group	at	the	4’-position	can	be	reduced	to	the	alcohol.	
The	results	indicated	that	four	equivalents	of	samarium	iodide	are	insufficient	to	reduce	
the	 ketone.	Adding	more	 reagents	 helped	 complete	 the	 conversion,	 but	 the	 yield	was	
not	optimal	because	compound	50,	generated	from	decomposition	of	ring	I,	was	found	
after	 addition	 of	methanol.	 The	 reaction	 time	 of	 the	 reduction	was	 also	 important.	 It	
required	 at	 least	 two	 hours	 for	 the	 reduction	 to	 complete,	 otherwise	 ketone	51	 and	
alcohol	50	were	the	dominant	products.	The	amount	of	methanol	added	was	critical	to	






the	 ring	 I	degradation	product	50	 becoming	major.	 In	 conclusion,	 the	best	 conditions	
were	using	six	equivalents	of	samarium	iodide,	first	reacting	at	-20	°C	for	one	hour,	then	
addition	 of	 10	 equivalents	 of	 methanol	 with	 stirring	 for	 another	 two	 hours	 at	 0	 °C,	
which	afforded	the	desired	product	in	a	modest	35%	yield.	
3.4 Synthesis	of	3’-deoxy	ribostamycin	52	
	 	 	 	 	 	 To	 test	 whether	 the	 same	 de-oxygenation	 method	 could	 be	 applied	 to	 other	
aminoglycosides,	3’-deoxy	ribostamycin	52	was	chosen	as	a	second	target.	Starting	from	
commercially	 available	 ribostamycin	 7,	 one	 equivalent	 of	
N-(benzyloxycarbonyloxy)succinimide	 and	 potassium	 carbonate	 were	 used	 to	
selectively	protect	 the	6’-amino	group,	as	 this	 is	 the	only	primary	amine	group	 in	 the	
molecule	 and	 is	 the	 most	 reactive	 one.	 Without	 further	 work	 up	 and	 purification,	
imidazolesulfonyl	azide	hydrochloride	salt,	potassium	carbonate	and	a	catalytic	amount	
of	 copper(II)	 sulfate	 were	 added	 into	 the	 reaction	 mixture	 to	 give	 the	 protected	
ribostamycin	derivative	53	in	38%	overall	yield.	Treatment	of	53	with	freshly	distilled	




in	 62%	 yield.	 The	 fully	 protected	 ribostamycin	 analog	 55	 was	 treated	 with	




provide	 alcohol	 56	 in	 71%	 yield.	 A	 similar	 protocol	 to	 that	 developed	 for	 3’-deoxy	
paromomycin	41	 outlined	 in	 Scheme	 5	 was	 applied	 to	 convert	 the	 amine	 protecting	
groups	from	azides	to	benzylcarbamates.	After	the	conversion,	alcohol	57	was	oxidized	
to	 ketone	 58	 with	 Dess-Martin	 periodinane	 in	 62%	 yield,	 which	 was	 treated	 with	
samarium	 iodide	 under	 the	 optimized	 conditions	 to	 form	 the	 protected	 3’-deoxy	











BnBr, NaH, TBAI TFA
i) Staudinger
i) SmI2, THF, -20 oC



























































































































Two steps yield: 42% Yield: 65%

















3’-Deoxy	neomycin	60	was	 the	 third	 target.	Based	on	 the	previous	experience,	
using	 neomycin	5	 as	 starting	material	was	 the	 first	 option.	 However,	 compared	with	
ribostamycin	7,	neomycin	5	has	two	primary	amino	groups	at	the	6’-	and	6’’’-positions.	
The	 selective	 protection	 strategy	 that	 worked	 on	 ribostamycin	 7	 gave	 a	 mixture	 of	
N6’-benzyl	 carbamate,	 N6’’’-benzyl	 carbamate	 and	 N6’,N6’’’-bis(benzyl	 carbamate)	
derivatives	when	applied	to	neomycin	5,	which	was	difficult	to	purify	and	led	to	a	low	
yield	of	 the	desired	product.	Thus,	paromomycin	6	was	chosen	as	alternative	starting	
material	 to	 synthesize	 the	 target	 compound.	 Neomycin	 derivative	 61,	 in	 which	 the	
secondary	hydroxy	group	at	the	4’-position	was	exposed	for	further	modification,	was	
prepared	from	paromomycin	6	following	a	literature	protocol.40,	154	Staudinger	reaction	
was	 applied	 to	 alcohol	 61	 to	 reduce	 all	 the	 azide	 groups,	 then	 the	 amines	 were	 all	
protected	 by	 benzylcarbamates	 by	 treatment	 with	 excess	 of	
N-(benzyloxycarbonyloxy)succinimide	and	potassium	carbonate.	The	two	step	reaction	
gave	alcohol	62	in	85%	yield.	Oxidation	of	62	using	Dess-Martin	periodinane	generated	
ketone	 63	 in	 79%	 yield,	 which	 was	 subjected	 to	 the	 optimized	 samarium	 iodide	









All	 the	 3’-deoxy	 4,5-AGA	 derivatives	 were	 submitted	 to	 the	 Böttger	 group	 in	
Zurich,	where	they	were	tested	for	antiribosomal	selectivity	(Table	5)	and	antibacterial	









i) SmI2, THF, -20 oC





















































































Yield: 85% Yield: 79%















Mit13	 Sel.	 A1555G	 Sel.	 Cyt14	 Sel.	




0.04	 109.0	 2725	 15.2	 380	 52.9	 1322	
Ribostamycin	7	 0.04	 203.9	 5097	 37.6	 940	 199.2	 4979	
3’-Deoxy	
ribostamycin	52	
0.05	 163.2	 3264	 59.0	 1179	 167.6	 3352	
Neomycin	5	 0.01	 2.0	 197	 0.26	 26	 21.8	 2175	
3’-Deoxy	
neomycin	60	
0.02	 2.6	 130	 0.28	 28	 34.4	 1718	
All	 three	3’-deoxy	modified	4,5-AGA	derivatives	showed	similar	activity	against	
the	bacterial	 ribosome	as	 their	parents.	For	3’-deoxy	paromomycin	41,	 the	 ribosomal	
selectivity	was	 increased	because	 its	 activity	 against	mitochondrial	 ribosome	 (Mit13),	
the	deafness	mutation	ribosome	(A1555G)	and	the	cytosolic	ribosome	(Cyt14)	were	all	
decreased.	On	the	other	hand,	compared	with	their	parents,	3’-deoxy	ribostamycin	52	
and	 3’-deoxy	 neomycin	 60	 both	 exhibited	 a	 loss	 of	 selectivity	 in	 the	 case	 of	
mitochondrial	ribosome	(Mit13)	and	cytosolic	ribosome	(Cyt14),	while	their	selectivity	
to	 the	 deafness	mutation	 ribosome	were	 almost	 the	 same.	 Unlike	 compound	41	 and	
























































































































4	 4	 4	 2	 2	 32-
64	
16	
The	 antibacterial	 activity	 results	 revealed	 that	 for	 the	MRSA	 and	E.	 coli	strains	
that	were	 tested,	 the	 3’-deoxy	modification	 did	 not	 changed	 the	 antibacterial	 activity	
compared	with	 their	parents.	For	P.	aeruginosa,	 compound	41,	52	 and	60	 all	 showed	
activity	 against	 some	 strains	 that	 were	 not	 susceptible	 to	 their	 mother	 compounds,	
which	 suggested	 that	 they	 were	 able	 to	 circumvent	 AGA	 resistance	 mechanisms.	
3’-Deoxy	 paromomyicn	 41	 and	 3’-deoxy	 ribostamycin	 52	 were	 screened	 for	 their	
antibacterial	activities	against	engineered	E.	coli	 that	expressed	different	AMEs	(Table	

















































2-4	 4	 1	 128	 64	 >128	 4	 2-4	
	 	 	 	 	 	 Compound	41	 and	52	 were	 both	 active	 against	 the	wild	 type	 AG006,	 and	 the	
strains	that	expressed	AAC(3)	(AG007),	ANT(2’’)	(AG008),	armA	(AG103),	and	AAC(2’)	
(AG105)	 resistance	 mechanisms,	 which	 were	 similar	 to	 the	 case	 of	 paromomycin	 6.	
However,	 all	 three	 compounds	 were	 deactivated	 by	 ANT(4’,4’’)	 (AG036)	 as	 well	 as	
APH(3’,5’’)	(AG037).	3’-Deoxy	ribostamycin	52	was	also	suffered	from	a	loss	of	activity	
to	 AG009	 strains,	 which	 contained	 the	 AAC(6’)	 resistance	 mechanism	 and	 was	
susceptible	to	paromomycin	6	and	3’-deoxy	paromomycin	41.	 	
3.7 Discussion	
	 	 	 	 	 	 In	 this	 chapter,	 two	different	methods	 to	synthesize	3’-deoxy	paromomycin	41	
were	 established.	The	 second	method,	which	utilized	 samarium	 iodide	 reduction	 as	 a	
key	 reaction,	 was	 proven	 to	 be	 useful	 in	 different	 aminoglycosides.	 Even	 though	 the	
overall	yield	was	only	modest,	it	provided	a	possible	way	to	effectively	achieve	3’-deoxy	




3’-deoxy	neomycin	60	were	also	 synthesized	 through	 this	 samarium	 iodide	 reduction	
method.	 All	 the	 3’-deoxy	 modified	 4,5-AGAs	 were	 tested	 for	 their	 antiribosomal	
activities	and	antibacterial	activities,	and	some	of	the	results	were	promising.	In	general,	
the	 3’-deoxy	 modification	 did	 not	 cause	 a	 reduction	 of	 activity	 against	 the	 bacterial	
ribosome,	which	suggested	that	the	3’-hydroxy	group	is	not	so	critical	for	binding	to	the	
decoding	A-site	 of	 bacteria.	 For	 the	 selectivity	 results,	 3’-deoxy	paromomycin	41	was	
more	 selective	 toward	 the	bacterial	 ribosomal	A-site,	while	3’-deoxy	 ribostamycin	52	
and	 3’-deoxy	 neomycin	 60	 suffered	 a	 slight	 loss	 in	 their	 selectivity.	 The	 selectivity	
difference	may	be	due	to	the	different	substitution	groups	at	the	6’-position	(hydroxyl	
group	on	paromomycin	versus	amino	group	on	neomycin	and	ribostamycin).	3’-Deoxy	
neomycin	 60	 was	 considered	 ototoxic	 because	 it	 exhibited	 good	 activity	 toward	 the	
mitochondrial	ribosome	and	the	deafness	mutation	ribosome.	The	reason	for	this	is	that	
compound	 60	 has	 an	 extra	 amine	 group,	 as	 its	 parent	 neomycin	 5,	 which	 helps	 the	
molecule	 bind	 more	 tightly	 not	 only	 to	 the	 bacteria	 decoding	 A-site,	 but	 also	 to	 the	
A-sites	 of	 mitochondrial	 and	 deafness	 mutation,	 by	 providing	 stronger	 electrostatic	
interaction	 under	 physiological	 conditions	 through	 protonation.	 The	 3’-deoxy	
modification	does	not	affect	antibacterial	activity,	as	compounds	41,	52	and	60	showed	
similar	activity	against	MRSA	and	E.	coli	compared	with	their	parents.	What	is	more,	41,	
52	 and	60	 were	 all	 active	 against	P.	 Aeruginosa	 strains	 that	 were	 not	 susceptible	 to	
paromomycin	6,	ribostamycin	7	and	neomycin	5,	supporting	the	hypothesis	of	restoring	




mechanism	 by	 3’-deoxy	 modification.	 A	 further	 antibacterial	 experiment	 was	
undertaken	 to	 test	 the	 effects	 of	 different	 AMEs	 on	 compound	 41	 and	 52.	 3’-Deoxy	
ribostamycin	52	was	affected	by	AAC(6’)	due	 to	 the	6’-amino	group.	Beside	 that,	 two	
3’-deoxy	4,5-AGA	derivatives	did	not	show	significant	changes	in	antibacterial	activities	
against	 the	 engineered	 E.	 coli	 strains.	 It	 is	 predictable	 that	 all	 the	 compounds	 were	
deactivated	 by	 ANT(4’,4’’)	 as	 the	 4’-postion	 of	 these	 compounds	 are	 exposed	 to	 be	
modified.	 But	 the	 effect	 of	 APH(3’,5’’)	 on	 the	 3’-deoxy	 4,5-AGA	 analogs	 suggests	 that	
5’’-position	is	also	an	important	target	of	this	enzyme	and	only	modifying	3’-position	is	
insufficient	to	completely	circumvent	this	resistance	mechanism.	In	order	to	develop	a	








the	 bacterial	 decoding	 A-site	 without	 losing	 antiribosomal	 and	 antibacterial	 activity,	
which	 made	 it	 a	 good	 substrate	 for	 further	 modification.	 A	 modification	 at	 the	
5’’-position	was	 decided	 for	 two	main	 reasons.	 First,	 the	 5’’-hydroxy	 group	 serves	 as	
hydrogen	 bond	 donor	 and	makes	 a	 hydrogen	 bond	 with	 N-7	 of	 the	 A1491G	 residue	
(Figure	 10b),	 which	 is	 important	 for	 the	 binding	 of	 4,5-AGAs.	 Some	 studies	 also	
hypothesize	 that	 the	 5’’-hydroxy	 group	 forms	 an	 intermolecular	 hydrogen	 bond	with	
the	 protonated	 2’-amine	 group	 to	 enforce	 the	 correct	 conformation	 for	 binding	 with	
bacterial	ribosome	(Figure	10b).138,	171	Second,	the	5’’-hydroxy	group	can	be	modified	by	
AMEs.	 The	 highly	 disseminated	 APH(3’)-IIIa	 has	 the	 capability	 to	 phosphorylate	 the	
5’’-position,	 in	 addition	 to	 the	 normal	 3’-position.	 Thus	 APH(3’)-IIIa	 deactivated	
3’-deoxy	 4,5-AGAs	 that	 have	 a	 5’’-hydroxy	 group	 as	 for	 example	 lividomycin	 A	 35	









Several	 attempts	 have	 been	 made	 to	 modify	 the	 5’’-position	 of	 4,5-AGAs.	 The	
5’’-deoxy	 paromomycin	 65,	 5’’-O-alkyl	 paromomycin	 66,	 and	 5’’-deoxy-5’’-fluoro	
paromomycin	 67	 derivatives	 suffer	 a	 significant	 loss	 of	 antibacterial	 activity	 (Figure	




In	 contrast,	 5’’-deoxy-5’’-amino	 modified	 4,5-aminoglycosides	 70,	 71	 and	 72	
retain	or	even	have	increased	antibacterial	activity	compared	with	their	parents	(Figure	
28).177-178	 These	 results	 indicate	 that	 the	 presence	 of	 a	 hydrogen	 bond	 donor	
substituent	 at	 the	 5’’-position	 is	 critical	 for	 binding	 to	 the	 bacterial	 ribosomal	 A-site.	
However,	the	introduction	of	the	amine	group	results	in	a	loss	of	selectivity	toward	the	
bacterial	ribosome	and	an	increase	toxicity,	because	the	extra	primary	amine	group	is	



































































R = H, 5’’-Deoxy paromomycin (65)
R = alkoxy group, 5’’-O-Alkyl paromomycin (66)



















R = OH, paromomycin 5’’-carboxylic acid (68)




attraction.	 Simple	 peptide	 analogs	 of	 3’-deoxy-5’’-amino	 neomycin	 71	 (compound	
73),179	 neomycin–anthroquinone	 conjugate	74,180	 and	neomycin	 dimer	75181	 that	 are	




Based	 on	 these	 observations,	 the	 Crich	 laboratory	 recently	 discovered	 that	
5’’-deoxy-5’’-formamido	paromomycin	76	 (Figure	29)	retains	the	antibacterial	activity	
of	the	parent	but	also	shows	increased	selectivity.	Accordingly,	in	combination	with	the	
samarium	 iodide	 reduction	 method	 developed	 in	 chapter	 three,	



















R = OH, 5’’-Deoxy-5’’-amino paromomycin (70)







































R = CH2NH2 or CH2NH(CO)CH2NH2
















































































intermediate	 78,	 which	 was	 readily	 obtained	 from	 paromomycin	 6	 by	 following	
literature	 protocol.154	 Selective	 silylation	 at	 the	 5’’-position	 with	 one	 equivalent	 of	
triisopropylsilyl	triflate	in	the	presence	of	2,6-lutidine	gave	silyl	ether	79	in	63%	yield,	
in	 which	 all	 hydroxy	 groups	 were	 protected	 as	 benzyl	 ethers	 using	 excess	 of	 benzyl	
bromide,	sodium	hydride	and	a	catalytic	amount	of	tetrabutylammonium	iodide	in	86%	
yield.	 When	 the	 fully	 protected	 intermediate	 80	 was	 obtained,	 the	 5’’-position	 was	
modified	 first,	 followed	 by	 modification	 of	 the	 3’-position.	 Trimethylphosphine	 and	
0.1M	 sodium	 hydroxide	 were	 used	 to	 reduce	 the	 azide	 groups	 of	 compound	 80	 to	
amines,	which	were	reacted	with	N-(benzyloxycarbonyloxy)succinimide	and	potassium	



































































Staudinger	 reaction,	 and	 freshly	 prepared	 formic	 acetic	 anhydride	 were	 applied	
sequentially	 to	 give	 the	 corresponding	 formamide	 84	 in	 67%	 yield	 over	 two	 steps.	
Alcohol	 85	 was	 acquired	 in	 75%	 yield	 by	 treating	 compound	 84	 with	 sodium	
cyanoborohydride	and	2	M	hydrogen	chloride	solution	in	diethyl	ether.	Oxidation	of	85	
with	Dess-Martin	periodinane	gave	the	corresponding	ketone	86	in	67%	yield,	to	which	
the	 optimized	 samarium	 iodide	 reduction	 conditions	discussed	 in	 chapter	 three	were	
applied	 and	 gave	 the	 protected	 3’,5’’-dideoxy-5’’-formamido	 paromomycin	 derivative	



































































































































































































i) SmI2, THF, 
-20 oC









































Yield: 63% Yield: 86%
Yield: 78%
Yield: 66%



















the	 3’-deoxy	 modification,	 was	 also	 examined	 for	 comparison	 purposes.	 Since	 the	
common	regioselective	4’,6’-O-benzylidene	acetal	hydrolysis	reaction	that	provides	the	
secondary	alcohol	at	4’-postion	takes	place	in	strong	acidic	conditions,	which	silyl	ether	
at	 5’’-position	 could	 not	 survive,	 the	 alternative	 reagent	 combination	 of	 borane	
trimethylamine,	copper(II)	triflate	and	a	catalytic	amount	of	triflic	acid	was	utilized	and	
alcohol	88	was	formed	in	35%	yield.	The	two	step	protocol	outlined	in	Scheme	8,	which	
transformed	 the	 azides	 into	 N-benzylcarbamates,	 was	 applied	 to	 alcohol	 88	 and	
provided	 intermediate	89	 in	 79%	 yield.	 Ketone	90	 was	 obtained	 by	 treatment	 of	89	
with	Dess-Martin	periodinane	in	75%	yield,	and	was	subjected	to	the	samarium	iodide	
reduction	to	cleave	the	3’-O-benzyl	group.	The	samarium	iodide	reduction	gave	alcohol	
91	 in	 35%	 yield,	 from	which	 the	 silyl	 ether	 at	 the	 5’’-position	was	 hydrolyzed	 using	
tetrabutylammonium	 fluoride	 giving	 the	4’,5’’-diol	 intermediate	92	 in	 75%	yield.	 The	
primary	 hydroxy	 group	 at	 the	 5’’-position	 was	 selectively	 tosylated	 in	 68%	 yield	 by	
treatment	with	p-toluenesulfonyl	chloride	and	pyridine.	Heating	with	sodium	azide	 to	
displace	 the	 5’’-tosyl	 group	 gave	 only	 a	 low	 yield	 of	 the	 desired	 azide.	 This	 could	 be	
improved	by	 first	protecting	the	4’-hydroxy	group	of	compound	93	as	a	 trimethylsilyl	
ether	 using	 hexamethyldisilazane,	 and	 then	 reacting	 with	 lithium	 azide	 and	 finally	
washing	 with	 1	 M	 hydrochloric	 acid	 to	 hydrolyze	 the	 trimethylsilyl	 ether	 protecting	
group	 after	 the	 reaction	 was	 completed.	 Intermediate	 94	 was	 treated	 with	
























































































































































































































by	 the	Böttger	 group	 in	 Zurich	using	 the	 same	methods	 outlined	 in	 chapter	 two.	 The	
results	 were	 compared	 with	 those	 of	 the	 parent	 paromomycin	 6,	 and	 two	 singly	







Mit13	 Sel.	 A1555G	 Sel.	 Cyt14	 Sel.	
Paromomycin	6	 0.03	 50.6	 1688	 5.5	 184	 10.6	 353	
3’-Deoxy	 	
paromomycin	41	
0.04	 109.0	 2725	 15.2	 380	 52.9	 1322	
5’’-Deoxy-5’’-formamido	
paromomycin	76	




0.04	 70.5	 1763	 37.1	 928	 78.5	 1963	
The	 cell-free	 translation	assays	 indicated	 that	 the	 combination	of	3’-deoxy	and	
5’’-deoxy-5’’-formamido	modifications	did	not	 cause	 reduction	 in	 the	 inhibition	of	 the	
bacterial	ribosome.	For	the	mitochondrial	ribosome,	the	IC50	value	of	compound	77	was	
bigger	than	that	of	paromomycin	6,	but	smaller	than	the	singly	modified	compounds	41	
and	 76.	 These	 results	 indicated	 that	 compared	 with	 paromomycin	 6,	 the	 doubly	
modified	 compound	 77	 showed	 a	 slight	 increase	 of	 selectivity	 in	 the	 case	 of	
mitochondrial	 binding	 A-site,	 but	 the	 increase	 is	 not	 as	 large	 as	 for	 the	 two	 singly	





was	 the	most	 selective	 compound	 toward	 the	 deafness	mutation	 A-site	 and	 cytosolic	
A-site.	 	
Table	9.	Antibacterial	activity	of	compound	77	(MIC,	μg/mL)	





































































modest	 activities	 against	 all	 three	 strains,	 while	 paromomycin	 6	 and	 compound	 76	
were	 completely	 inactive	 and	 compound	 41	 was	 only	 active	 against	 two	 of	 them	
(AG031	 and	 AG032).	 Since	 compound	 77	 retained	 antibacterial	 activity	 against	 the	
clinical	 isolates	 of	 E.	 coli,	 engineered	 E.	 coli	 strains	 that	 contain	 different	 resistance	








Strains	 AG006	 AG009	 AG036	 AG037	 AG103	
Resistance	mechanism	 -	 AAC(6’)	 ANT(4’,	4’’)	 APH(3’,	5’’)	 armA	
Paromomycin	6	 2	 4-8	 >128	 >128	 4	
3’-Deoxy	paromomycin	41	 1-2	 8	 128	 >128	 8	
5’’-Deoxy-5’’-formamido	
paromomycin	76	
1-2	 -	 -	 128	 -	
3’,5’’-Dideoxy-5’’-formami
do	paromomycin	77	
2	 8	 64-128	 4	 32	
	 	 	 	 	 	 Paromoycin	 6,	 two	 singly	 modified	 derivatives	 41	 and	 76,	 and	 the	 double	
modified	 compound	 77	 were	 screened	 for	 their	 antibacterial	 activities	 against	
engineered	E.	coli	and	the	results	are	presented	in	Table	10.	All	four	compounds	shared	
similar	 activity	 against	 the	 parent	wild	 type	 AG006	 strain	 and	 the	 AG009	 strain	 that	
expressed	AAC(6’).	In	the	meantime,	all	the	compounds	were	deactivated	by	the	ANT(4’,	
4’’)	 resistance	 mechanism.	 Excitingly,	 3’,5’’-dideoxy-5’’-formamido	 paromomycin	 77	
exhibited	good	activity	against	the	AG037	strain	that	contains	the	APH(3’,	5’’)	resistance	
mechanism,	 which	 affects	 not	 only	 the	 parent	 paromomycin	 6,	 but	 also	 the	 singly	
modified	compounds	41	and	76.	Another	interesting	discovery	was	that	compound	77	
exhibited	reduced	activity	against	the	AG103	strain	that	expressed	the	armA	resistance	
mechanism	 whereas	 neither	 paromomycin	 6	 nor	 3’-deoxy	 paromomycin	 41	 were	
affected	by	this	mechanism.	
4.4 Discussion	







Two	different	modification	 schemes	were	 carried	 out	 for	 comparison	purpose.	 In	 the	
first	 one	 the	 5’’-position	 was	 modified	 before	 the	 3’-position,	 while	 the	 second	 one	
reversed	 the	 sequence.	 The	 first	 route	 required	 ten	 steps	 starting	 from	 the	 common	
intermediate	80	and	gave	the	final	product	in	an	overall	yield	of	2.4%.	In	comparison,	
the	 second	route	needed	an	extra	 step	 to	protect	 the	hydroxy	group	at	 the	4’-positon	
while	 modifying	 the	 5’’-position,	 and	 the	 overall	 yield	 was	 only	 0.9%.	 The	 major	
difference	 came	 from	 the	 regioselective	 cleavage	 of	 the	 benzylidene	 acetal	 at	 the	
4’,6’-position.	The	commonly	used	sodium	cyanoborohydride	conditions	that	expose	the	
secondary	hydroxy	 group	at	 the	4’-position	 selectively	 require	 the	use	of	 strong	 acid,	
which	was	 not	 compatible	 with	 the	 second	 route	 because	 of	 the	 silyl	 ether	 group	 at	
5’’-postion.	The	yield	of	 the	alternative	reaction	was	unsatisfactory	and	decreased	 the	
overall	efficiency	of	the	second	route.	
	 	 	 	 	 	 Most	bioactivity	data	indicated	that	the	doubly	modified	paromoycin	analog	77	
was	a	promising	compound.	The	combination	of	3’-deoxy	and	5’’-deoxy-5’’-formamido	
modifications	into	a	single	compound	did	not	affect	the	affinity	of	compound	77	toward	
the	bacterial	 ribosomal	A-site,	which	was	 the	same	as	 that	of	 the	 two	singly	modified	








MRSA	 and	 E.	 coli	 was	 the	 same	 as	 that	 of	 the	 parent	 and	 the	 two	 singly	 modified	
compounds.	 Compound	 77	 also	 exhibited	 modest	 activities	 against	 all	 three	 P.	
aeruginosa	 strains	 tested,	 which	 was	 important	 because	 these	 strains	 are	 not	
susceptible	 to	 paromomycin	 6	 and	 5’’-deoxy-5’’-formamido	 paromomycin	 76,	 while	
3’-deoxy	 paromomycin	41	 was	 only	 active	 against	 two	 of	 them	 (AG031	 and	 AG032).	
These	results	indicated	that	the	doubly	modified	paromomycin	derivative	77	is	a	better	
antibiotic	 compared	 with	 two	 singly	 modified	 compounds	 41	 and	 76.	 Further	
experiments	 on	 the	 engineered	 E.	 coli	 strains	 demonstrated	 the	 efficacy	 of	 the	
modifications	made	on	paromomycin	6	in	overcoming	different	resistance	mechanisms.	
The	doubly	modified	compound	77,	 as	well	as	paromoycin	6	 and	 two	singly	modified	
compound	41	 and	76,	 inhibited	 the	growth	of	bacteria	 that	expressed	AAC(6’),	which	
would	be	expected	because	all	these	compounds	are	paromomycin	or	its	analogs	and	do	
not	have	a	6’-amino	group.	Deactivation	of	all	the	tested	compounds	by	ANT(4’,	4’’)	was	
also	 predictable	 as	 the	 4’-hydroxy	 group	 of	 these	 compounds	 is	 available	 for	
modification	by	this	enzyme.	The	most	valuable	result	was	the	demonstration	that	the	
3’,5’’-double	 modified	 paromomycin	 derivative	 77	 showed	 good	 activity	 against	
bacteria	strains	that	carried	the	APH(3’,	5’’)	resistance	mechanism,	which	affected	not	
only	paromomycin	6,	but	also	3’-deoxy	paromomycin	41,	and	5’’-deoxy-5’’-formamido	




armA	 resistance	mechanism	 (AG103).	 This	mechanism	 is	 not	 supposed	 to	 deactivate	
4,5-AGAs,	 as	 is	 demonstrated	 for	 paromomycin	 6	 and	 3’-deoxy	 paromomycin	 41.	
However,	 the	 activity	 of	 compound	77	 against	 the	AG103	 strain	was	 eight	 times	 less	
than	that	of	paromomycin	6.	Perhaps,	modifying	the	3’-position	and	5’’-positions	at	the	
same	time	may	change	the	binding	mode	of	compound	77,	making	rings	III	and	IV	closer	








The	 3’,5’’-dideoxy-5’’-formamido	 paromomycin	 77	 exhibited	 good	 activity	
toward	 the	bacterial	 ribosome,	as	well	as	good	ribosomal	selectivity	and	antibacterial	
activity.	 The	 antibacterial	 experiments	 against	 engineered	 E.	 coli	 strains	 proved	 that	
this	 compound	 was	 active	 against	 bacteria	 that	 contain	 the	 APH(3’)-IIIa	 resistance	






in	 the	 presence	 of	 Mg2+	 ions.17	 ANT(4’)	 has	 been	 found	 in	 a	 variety	 of	 bacteria	 and	
produces	 resistance	 to	 a	 broad	 array	 of	 aminoglycosides	 such	 as	 amikacin	 4,	
tobramycin	11	and	kanamycin	2	by	O-adenylation	of	the	4’-hydroxy	group.109	 	
Several	attempts	have	been	made	to	modify	the	4’-position	of	4,5-AGAs	in	order	
to	 block	 the	 ANT(4’)	 resistance	 mechanism,	 and	 to	 increase	 the	 selectivity	 for	 the	
bacterial	 ribosome	 thereby	 alleviating	 the	 toxicity	 problems.	 4’-Deoxy	 neomycin	 95	
(Figure	 30)	 maintains	 the	 intrinsic	 activity	 of	 neomycin	 5,	 while	 its	 activity	 against	





fluorine	 (Figure	 30,	 96)	 increases	 the	 potency	 against	 aminoglycoside	 susceptible	
bacterial	strains	and	leads	to	the	evasion	of	ANT(4’).40	4’-O-Aralkyl	(Figure	30,	97),	as	
well	 as	 4’-O-alkyl	 (Figure	 30,	98)	modifications	 of	 paromomycin	6	 confer	 substantial	
antibacterial	 activity	 in	 vitro	 and	 in	 vivo,	 accompanied	 by	 little	 hearing	 loss	 or	
morphological	 cochlear	 damage.146-147	 The	 4′-O-β-D-xylopyranosyl	 paromomycin	 99	




























R =H, 4’-deoxy neomycin 95

















R = aralkyl, 4’-O-aralkyl paromomycin 97


























An	 effective	 procedure	 was	 developed	 by	 the	 Crich	 laboratory	 to	 synthesize	
4’-deoxy-4’-C-propyl	paromomycin	100	 starting	 from	paromomycin	6.	One	of	 the	key	
steps	 in	 this	 procedure	 installed	 an	 equatorial	 C-allyl	 group	 at	 the	 4’-position	 (104)	
through	 a	 radical	 reaction	 between	 the	 axial	 iodide	 103,	 which	 was	 generated	 from	





The	 same	 strategy	 was	 applied	 to	 intermediate	 87,	 which	 was	 obtained	 as	
outlined	 in	 chapter	 four.	 Unfortunately,	 treatment	 of	 87	 with	 triflic	 anhydride	 and	
pyridine	 followed	 by	 SN2	 substitution	 with	 sodium	 iodide	 did	 not	 afford	 the	 desired	



















































































































result	 of	 dehydration	 of	 the	 formamide	 group	 at	 the	 5’’-position	 (106,	 Scheme	 11).	
Instead	of	 triflation,	 tosylation	and	mesylation	at	 the	4’-position	were	also	 tested,	but	






Eventually,	 a	 glycosylation	 strategy,	 which	 was	 also	 developed	 by	 the	 Crich	
laboratory	 in	 order	 to	 synthesize	 3’,4’-dideoxy-4’-C-propyl	 paromomycin	 110	 using	

































































































































H2Ni) TTBP, Tf2O, cyclohexene, 
DCM, 4A M.S., -60 oC
ii) NaOMe, MeOH, rt
iii) 80% AcOH/THF (2: 1), 60 oC
iv) H2 ballon, Pd(OH)2/C,  








The	 Crich	 laboratory	 developed	 the	 synthetic	 method	 for	 donor	 108	 when	
compound	 110	 was	 synthesized.	 A	 literature	 protocol	 was	 followed	 to	 prepare	
intermediate	115	from	commercially	available	levoglucosan	111.184	Two	equivalents	of	
p-toluenesulfonyl	 chloride	 were	 used	 to	 selectively	 tosylate	 positions	 2	 and	 4	 of	
levoglucosan	 111	 in	 the	 presence	 of	 pyridine	 at	 low	 temperature	 to	 achieve	
intermediate	112,	which	was	treated	with	sodium	methoxide	to	give	epoxide	113	in	68%	
yield	 over	 two	 steps.	 The	 allyl	 Grignard	 reagent	was	 applied	 and	 an	 allyl	 group	was	
installed	 at	 the	 4-position	with	 epoxide	 ring	 opening	 in	 49%	yield.	 Alcohol	114	 then	
was	reacted	with	sodium	hydride	and	epoxide	115	was	 formed	 in	83%	yield.	Heating	
with	benzylamine	opened	the	epoxide	ring	of	intermediate	115	and	the	2-benzylamino	
substituent	 was	 introduced	 in	 67%	 yield.	 Hydrogenolysis	 over	 palladium	 on	 carbon,	
followed	 by	 treatment	 with	 benzyl	 chloroformate	 and	 sodium	 carbonate	 afforded	
intermediate	117	 from	compound	116	 in	74%	yield	over	two	steps.	Alcohol	117	was	
first	 treated	with	 sodium	hydride,	 and	 then	 reacted	with	 carbon	disulfide	and	methyl	
iodide	 to	 form	 the	 xanthate	 118	 in	 93%	 yield,	 which	 was	 subjected	 to	 radical	
de-oxygenation	 with	 azobisisobutyronitrile	 as	 radical	 initiator	 and	
tris(trimethylsilyl)silane	 as	 hydrogen	 radical	 donor	 in	 benzene	 at	 reflux.	 The	
de-oxygenation	 product	 119	 was	 obtained	 in	 84%	 yield	 from	 this	 reaction.	 The	





catalytic	amount	of	 copper(II)	 sulfate,	when	azide	120	was	 formed	 in	78%	yield	over	
two	 steps.	 Preparation	 of	 intermediate	 121	 was	 completed	 by	 anomeric	 sulfide	
formation	 reaction	 using	 trimethyl(phenylthio)silane	 and	 zinc(II)	 iodide,185	 and	 basic	
work	up	with	potassium	carbonate	in	83%	yield.	A	small	adjustment	was	made	in	order	
to	 take	 advantage	 of	 the	 synthetic	 intermediate	 outlined	 in	 previous	 chapter	 and	
simplify	 the	 de-protection	 step.	 Instead	 of	 installing	 an	 ester,	 the	 6-hydroxy	 group	 of	
compound	 121	 was	 protected	 as	 a	 benzyl	 ether	 in	 the	 presence	 of	 sodium	 hydride,	
benzyl	bromide	and	tetrabutylammonium	iodide.	Finally,	oxidation	of	intermediate	122	












































































































in	 the	 literature.186-187	 The	 strategy	 is	 constituted	 of	 regioselective	 protection	 of	 four	
amine	 groups	 in	 paromomycin	 6	 followed	 by	 diazotization	 at	 the	 2’-position	 with	
sodium	nitrite	in	aqueous	acetic	acid	to	degrade	the	ring	I	(Scheme	14).	However,	this	
synthesis	 does	 not	 permit	 selective	 functionalization	 of	 the	 5’’-position	 as	 needed	 for	
the	 target	 compound	 101.	 Therefore	 an	 alternative	 method	 developed	 in	 the	 Crich	





in	 order	 to	 hydrolyze	 the	 benzylidene	 acetal.	 But	 this	 was	 accompanied	 by	 the	




























































i) Cbz-Cl, Na2CO3, 
MeOH/H2O, rt










53%	 yield.188	 Ring	 I	 then	 was	 degraded	 to	 glycosyl	 acceptor	 129	 by	 sequential	





in	 Figure	 32.	 The	 4’-	 and	 6’-hydroxy	 groups	 of	 compound	128	 were	 oxidized	 to	 the	
corresponding	 ketone	 and	 aldehyde	 (130)	 using	 the	 Dess-Martin	 periodinane,	 after	
which	 a	 hydroxy	 group	 was	 installed	 at	 the	 5’-position	 on	 treatment	 with	
















































































protecting	 group	 at	 the	 5’’-position	 using	 tetrabutylammonium	 fluoride	 afforded	
alcohol	133	 in	36%	yield	over	 two	steps	 (Scheme	16).	Two	different	synthetic	 routes	
were	tried	to	access	the	5’’-deoxy-5’’-formamido	modification.	The	first	route	included	
azide	 displacement	 at	 the	 5’’-position	 followed	 by	 reduction	 and	 formylation,	 as	
discussed	 in	 chapter	 four.	 In	 order	 to	 avoid	 side	 reactions	 caused	 by	 the	 other	 azide	
groups,	 intermediate	 133	 was	 treated	 with	 trimethylphosphine	 and	 0.1	 M	 sodium	
hydroxide,	 and	 then	 N-(benzyloxycarbonyloxy)succinimide	 and	 potassium	 carbonate	
were	 added	 to	 form	 alcohol	 134	 in	 74%	 yield.	 A	 tosyl	 group	 was	 installed	 at	 the	





























































4-dimethylaminopyridine,	 and	 then	 displaced	 by	 an	 azido	 group	 using	 sodium	 azide.	
The	 azide	 intermediate	135,	 obtained	 in	 79%	 yield,	was	 subjected	 to	 the	 Staudinger	
reaction	 to	 afford	 amine	 136.	 Unfortunately,	 formylation	 of	 amine	 136	 with	 formic	
acetic	 anhydride	 or	 N-(diethylcarbamoyl)-N-methoxyformamide	 generated	 two	
inseparable	isomers,	both	of	which	had	the	correct	molecular	weight	according	to	mass	
spectrometer	 (Scheme	 16).	 The	 1H-NMR	 spectra	 of	 these	 isomers	 were	 unresolvable	

















































































































































group	 in	 Zurich	 to	 test	 for	 antiribosomal	 activity	 and	 antibacterial	 activity	 using	 the	







































































































































293	 573	 411	 804	
Compared	 with	 paromomycin	 6,	 singly	 modified	 derivative	 100	 and	 doubly	
modified	derivative	77,	the	triply	modified	compound	101	exhibited	a	significant	lost	of	
antiribosomal	activity.	The	activity	of	compound	101	against	bacterial	 ribosomes	was	
seventeen	 times	 less	 than	 that	 of	 the	 paromomycin	6.	 The	 activity	 of	 compound	101	
toward	the	mitochondrial	ribosome	A-site	was	comparably	reduced,	which	leads	similar	
selectivity	 compared	 with	 paromoycin	 6.	 A	 slightly	 increase	 in	 selectivity	 toward	
deafness	mutation	ribosomal	A-site	and	cytosolic	ribosomal	A-site	was	observed,	as	the	

































































32	 16	 32	 32	 32	 >64	 >64	 >64	
	 	 	 	 	 	 In	general,	the	combination	of	three	different	modifications	resulted	in	reduced	








In	 this	 chapter,	 two	 synthetic	 approaches	 were	 tried	 to	 synthesize	 triply	
modified	 paromomycin	 analog	 101.	 The	 first	 scheme	 involved	 samarium	 iodide	
reduction	as	discussed	in	chapter	three;	azide	substitution,	reduction	and	formylation	at	




Crich	 laboratory	 using	 (allylsulfonyl)benzene.	 Introduction	 of	 an	 axial	 iodide	 to	 the	
4’-position	 is	 a	prerequisite	 reaction	 for	 the	 radical	 alkylation,	which	did	not	proceed	
well	in	this	scheme.	The	second	scheme	utilized	a	glycosylation	reaction	to	construct	the	




Unfortunately,	 the	 combination	 of	 3’-deoxy,	 4’-deoxy-4’-C-propyl	 and	
5’’-deoxy-5’’-formamido	 modifications	 into	 a	 single	 molecule	 caused	 a	 significant	
reduction	 of	 activity	 against	 the	 prokaryotic	 and	 eukaryotic	 ribosomes,	 such	 that	 the	
triply	modified	compound	101	was	not	considered	as	active	enough	to	be	useful.	The	
antibacterial	 activity	 results	 provided	 the	 same	 conclusion.	 Compound	 101	 showed	
noticeably	 decreased	 activity	 against	 clinical	 isolates	 of	MRSA	 and	 E.	 coli	 that	 were	
tested	compared	with	 the	parent	paromomycin	6,	 the	singly	modified	compound	100	
and	the	doubly	modified	compound	77.	Although	this	compound	inhibited	the	growth	
of	 AG039	 and	 AG042	 strains,	which	were	 not	 susceptible	 to	 paromomycin	6	 and	 the	
doubly	 modified	 derivative	 77,	 the	 activity	 was	 much	 worse	 than	 that	 of	 the	 singly	
modified	 compound	 100.	 Perhaps	 the	 combination	 of	 3’-deoxy,	 4’-deoxy-4’-C-propyl	
and	 5’’-deoxy-5’’-formamido	 modifications	 caused	 a	 conformational	 change	 of	 the	
molecule,	which	destroyed	the	interaction	between	the	molecule	and	the	binding	A-site.	 	




paromomycin	6	 was	 successfully	 executed,	 but	 the	 unexpected	 loss	 of	 activity	 in	 the	
triply	 modified	 paromomycin	 derivative	 101	 indicated	 the	 4’-deoxy-4’-C-propyl	











were	 applied	 to	 determine	 the	 influences	 of	 these	 modifications	 on	 antiribosomal	


















the	 3’-deoxygenation	modification	was	 achieved	 by	 samarium	 iodide	 reduction.	 Even	
though	 the	 overall	 yield	 was	 modest,	 this	 novel	 synthetic	 method	 showed	 good	
compatibility	 to	 the	 complex	 AGA	 molecules.	 All	 the	 3’-deoxy	 modified	 compounds	
retained	 their	 antiribosomal	 and	 antibacterial	 activity	 and	 were	 active	 P.	 Aeruginosa	
strains	 that	 were	 not	 susceptible	 to	 their	 parents.	 Further	 biological	 experiment	 on	
3’-deoxy	 paromomycin	 and	 3’-deoxy	 ribostamycin	 showed	 that	 these	 singly	modified	
compounds	 were	 still	 affected	 by	 APH(3’,5’’)	 resistance	 mechanism,	 so	 double	
modification	is	required.	




the	 activity	 against	 bacterial	 ribosomal	 A-site	 and	 increased	 selectivity	 toward	 the	
cytosolic	ribosomal	A-site	and	the	deafness	mutation	ribosomal	A-site.	It	was	also	active	
against	 all	 three	P.	 aeruginosa	 strains	 tested	 in	 the	 antibacterial	 experiment.	 Further	
experiments	 demonstrated	 that	 this	 3’,5’’-double	 modified	 paromomycin	 derivative	
circumvent	 the	 APH(3’,5’’)	 resistance	 mechanism.	 All	 these	 results	 showed	 that	
3’,5’’-dideoxy-5’’-formamido	 paromomycin	 can	 be	 a	 good	 drug	 candidate	 and	 a	 good	
substrate	for	further	modification.	






ribosomes	 were	 significantly	 reduced.	 The	 antibacterial	 experiment	 against	 clinical	
isolates	provided	same	conclusion.	These	result	suggested	that	the	4’-deoxy-4’-C-propyl	
modification	was	not	compatible	with	3’,5’’-dideoxy-5’’-formamido	double	modification.	
Overall,	 several	 modifications	 have	 been	 made	 on	 4,5-AGAs,	 including	
paromomycin,	 ribosatmycin	 and	 neomycin.	 Some	 modified	 compounds	 show	 good	
antibacterial	 activity	 and	 circumvent	 known	AMEs.	 These	 results	 prove	 that	 the	 next	







All	 reagents	 and	 solvents	were	 purchased	 from	 commercial	 suppliers	 and	were	 used	
without	further	purification	unless	otherwise	specified.	Chromatographic	purifications	
were	 carried	 out	 over	 silica	 gel	 (230	 –	 400	 mesh)	 and	 Sephadex	 C-25.	 Analytical	
thin-layer	 chromatography	 (TLC)	was	preformed	with	 pre-coated	 glass	 backed	plates	
(w/UV	254).	TLC	was	visualized	by	UV	irradiation	(254	nm)	or	by	staining	with	sulfuric	









ntaazido	 paromomycin	 (32):	 Under	 an	 argon	 atmosphere,	 a	 soln.	 of	31	 (2.7	 g,	 2.0	
mmol)	 in	 dry	 dichloromethene	 (55	mL)	was	 cooled	 to	 0	 °C,	 treated	with	 2	M	borane	
dimethyl	sulfide	in	tetrahydrofuran	(9.5	mL,	19	mmol)	and	1	M	dibutylboron	triflate	in	
dichloromethane	(1.9	mL,	1.9	mmol),	and	stirred	at	room	temperature	for	4	h.	Saturated	




organic	 layer	 was	 washed	 with	 brine,	 dried	 with	 sodium	 sulfate,	 filtered,	 and	
concentrated	 under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	
(hexane:	 ethyl	 acetate	 4:1)	 gave	32	 as	 a	white	 solid	 (2.35	 g,	 87%).	Rf	 (hexane:	 ethyl	
acetate	2:1)	0.50.	[α]23D 	 =	+	6.4°	(c	=	1.0,	chloroform).	1H	NMR	(500	MHz,	chloroform-d)	
δ	7.52	–	7.03	(m,	35H,	aromatic),	6.17	(d,	J1′-2′	=	3.6	Hz,	1H,	H1′),	5.71	(d,	J1′′-2′′	=	5.6	Hz,	
1H,	H1′′),	5.00	(d,	 J	=	10.6	Hz,	1H,	 -OCH2Ph),	4.92	(d,	 J1′′′-2′′′	=	1.6	Hz,	1H,	H1′′′),	4.90	–	
4.81	(m,	3H,	-	OCH2Ph),	4.74	(d,	J	=	10.6	Hz,	1H,	-	OCH2Ph),	4.68	–	4.58	(m,	3H,	-	OCH2Ph),	








NMR	 (125	 MHz,	 chloroform-d)	 δ:	 138.4	 –	 136.9	 (tertiary	 aromatic),	 128.70	 -	 127.1	
(aromatic),	 106.2	 (C1′′),	 98.6	 (C1′′′),	 95.8	 (C1′),	 84.2	 (C6),	 82.5	 (C2′′),	 82.1	 (C5),	 82.0	
(C4′′),	 79.8	 (C3′),	 77.6	 (C4′),	 75.5	 (C3′′),	 75.4	 (PhCH2),	 75.0	 (PhCH2),	 74.9	 (C4),	 74.7	
(PhCH2),	 74.4	 (C5′′′),	 73.2	 (PhCH2),	 73.2	 (PhCH2),	 72.8	 (C3′′′),	 72.4	 (PhCH2),	 71.7	
(PhCH2),	71.6	(C5′),	71.5	(C4′′′),	70.3	(C5′′),	63.2	(C2′),	61.5	(C6′),	60.4	(C3),	60.1	(C1),	






ntaazido-paromomycin-6′-carboxylic	 Acid	 (33):	 Potassium	 bromide	 (18	 mg,	 0.15	




was	 stirred	 at	 room	 temperature	 for	 another	 18	 h.	 The	 reaction	mixture	was	 diluted	
with	ethyl	acetate,	washed	with	1	M	hydrochloric	acid	and	brine.	The	organic	layer	was	
dried	 with	 sodium	 sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 Flash	
column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	 acetate	 2:1)	 gave	33	 as	 a	 light	
yellow	solid	(133	mg,	68%).	Rf	(hexane:	ethyl	acetate	1:2)	0.60.	[α]23D 	 =	+	5.9°	(c	=	1.0,	
chloroform).	1H	NMR	(500	MHz,	chloroform-d)	δ	7.43	–	7.12	(m,	35H,	aromatic),	6.15	(d,	























and	 triethylamine	 (0.11	 mL,	 0.8	 mmol).	 After	 stirring	 for	 3	 h	 at	 -5	 °C,	
tert-dodecylmercaptan	 (0.11	mL,	 0.5	mmol)	was	 added	under	 an	 argon	 atomesphere,	
and	the	reaction	mixture	was	irradiated	with	a	Utilitech	Bright	White	Spiral	CFL	Light	
Bulb	(Color	temperature:	3500	K;	Lumens:	1600;	120	V;	60	Hz;	23	W,	0,308	A)	for	1.5	h.	


















1.39	(q,	 J	=	 J2ax-2eq	=	12.7	Hz,	 J2ax-1	=	12.7	Hz,	 J2ax-3	=	12.7	Hz,	H2ax).	13C	NMR	(125	MHz,	
chloroform-d)	 δ:	 138.3	 –	 136.9	 (tertiary	 aromatic),	 128.7	 –	 127.4	 (aromatic),	 106.0	
(C1′′),	 98.6	 (C1′′′),	 95.9	 (C1′),	 84.2	 (C6),	 82.5	 (C2′′),	 82.0	 (C5),	 81.8	 (C4′′),	 79.0	 (C3′),	
78.0	(C4′),	75.5	(C4),	75.3	(C3′′),	75.0	(PhCH2),	74.9	(PhCH2),	74.3	(C5′′′),	73.3	(PhCH2),	
73.2	 (PhCH2),	73.0	 (C3′′′),	72.9	 (PhCH2),	72.4	 (PhCH2),	71.7	 (PhCH2),	71.4	 (C4′′′),	70.1	
(C5′′),	 62.9	 (C2′),	 60.8	 (C5′),	 60.3	 (C3),	 60.0	 (C1),	 57.3	 (C2′′′),	 51.0	 (C6′′′),	 32.6	 (C2).	
ESI-HRMS:	m/z	calcd	for	C71H75N15NaO13	[M+Na]+	1368.5566,	found	1368.5564.	
6′-Deshydromethyl	paromomycin	pentaacetate	 salt	 (30):	A	stirred	soln.	of	34	 (33	
mg	0.024	mmol)	in	a	mixture	of	(1,4-dioxane/water/acetic	acid	1/2/0.2,	0.35	mL)	was	
treated	 with	 palladium	 hydroxide	 on	 carbon	 (33	mg),	 and	 stirred	 under	 a	 hydrogen	
















H2eq),	 1.81	 (s,	 15H,	 CH3CO2H),	 1.74	 –	 1.62	 (m,	 1H,	H2ax).	13C	NMR	 (125	MHz,	 D2O)	 δ:	
180.9	(CH3COOH),	110.2	(C1′′),	98.1	(C1′),	95.4	(C1′′′),	83.5	(C5),	81.2	(C4′′),	78.4	(C4),	
75.7	 (C3′′),	 73.2	 (C2′′),	 71.8	 (C6),	 70.2	 (C5′′′),	 67.8	 (C3′),	 67.6	 (C3′′′),	 67.2	 (C4′),	 66.8	
(C4′′′),	65.3	(C5′),	60.7	(C5′′),	51.4	(C2′′′),	50.8	(C2′),	49.7	(C1),	48.4	(C3),	40.4	(C6′′′),	








mmol),	 potassium	 carbonate	 (842	mg,	 6.1	mmol)	 and	 copper(II)	 sulfate	pentahydrate	
(15	 mg,	 0.061	 mmol),	 and	 stirred	 at	 room	 temperature	 for	 24	 h.	 All	 solvent	 was	
removed	under	reduced	pressure,	the	remaining	residue	was	dissolved	in	methanol	and	
filtered.	 The	 filtrate	 was	 concentrated	 under	 reduced	 pressure.	 After	 purification	 by	
flash	column	chromatography	over	silica	gel	(ethyl	acetate:	methanol	5:1),	the	resulting	
compound	(401	mg)	was	dissolved	in	water	(22	mL)	and	sodium	periodate	(225	mg,	1.1	
mmol)	was	added.	The	reaction	mixture	was	stirred	 in	 the	dark	at	 room	temperature	




acid	 (0.9	mL)	 and	phenylhydrazine	 (0.9	mL)	 for	3	h.	The	mixture	was	 extracted	with	















J2eq-3	=	4.2	Hz,	1H,	H2eq),	1.38	(q,	 J2ax-1	=	 J2ax-3	=	 J2ax-2eq	=	12.6	Hz,	1H,	H2ax).	 13C	NMR	
(151	MHz,	CD3OD)	δ	107.1	(C1’’),	98.2	(C1’’’),	95.3	(C1’),	83.8	(C4),	81.9	(C4’’),	75.5	(C6),	





and	 heated	 at	 60	 °C	 for	 1	 h.	 Then	 deionized	 water	 (1	 mL)	 was	 added	 and	 reaction	
mixture	was	 heated	 at	 60	 °C	 for	 16	 h.	 The	 reaction	mixture	was	 concentrated	 under	
reduced	 pressure	 and	 purified	 by	 Sephadex	 C-25	 column	 chromatography	 (gradient	
elution	 of	 0.1%	 -	 1.0%	 ammonium	 hydroxide	 in	 deionized	 water).	 The	
product-containing	 fractions	 were	 combined,	 glacial	 acetic	 acid	 (50	 μL,	 0.81	 mmol)	
added,	and	freeze	dried	to	give	41	as	a	white	solid	(15.1	mg,	56%	as	pentaacetate	salt).	
[α]23D 	 =	+	62.5°	(c	=	1.0,	H2O).	Lit	[α]23D 	 =	+	62.0°	(c	=	1.0,	H2O).165	1H	NMR	(600	MHz,	
D2O)	δ	5.37	(d,	J1’-2’	=	3.5	Hz,	1H,	H1’),	5.13	(d,	J1’’-2’’	=	2.0	Hz,	1H,	H1’’),	5.09	(d,	J1’’’-2’’’	=	1.5	









J3’eq-3’ax	 =	 11.2	 Hz,	 J3’eq-2’	 =	 J3’eq-4’	 =	 4.2	 Hz,	 1H,	 H3’eq),	 1.86	 –	 1.69	 (m,	 16H,	 H3’ax,	
CH3CO2H),	1.65	(q,	J2ax-2eq	=	J2ax-3	=	J2ax-1	=	11.2	Hz,	1H,	H2ax).	13C	NMR	(151	MHz,	D2O)	δ	
180.49	(CH3CO2H),	110.0	(C1’’),	95.3	(C1’’’),	94.2	(C1’),	84.0	(C5),	81.2	(C4’’),	77.8	(C5’),	





paromomycin	 (47)	 	 1.0	 M	 trimethylphosphine	 in	 tetrahydrofuran	 (6	 mL,	 6	 mmol)	
was	added	into	a	stirred	soln.	of	compound	46	(800	mg,	0,6	mmol)	in	tetrahydrofuran	
(16	mL),	and	the	mixture	was	heated	at	70	°C	for	0.5	h.	Then	0.1	M	sodium	hydroxide	
solution	 (6	mL)	was	 added	and	 the	 temperature	was	maintained	at	70	 °C	 for	6	h.	All	
solvent	 was	 evaporated	 under	 reduced	 pressure	 and	 the	 residue	 was	 dissolved	 in	
methanol	 (20	mL).	 Sodium	 carbonate	 (900	mg,	 8.4	mmol)	 and	 benzyl	 chloroformate	








0.8,	 dichloromethane).	 Rf	 (hexane:	 ethyl	 acetate	 1:1)	 0.55.	 ESI-HRMS:	m/z	 calcd	 for	
C112H117N5NaO24	[M+Na]+	1939.8020,	found	1939.8017.	This	compound	was	employed	




was	 treated	 with	 Dess-Martin	 periodinane	 (125	 mg,	 0.3	 mmol)	 and	 stirred	 at	 room	
temperature	for	18	h.	The	reaction	mixture	was	diluted	with	ethyl	acetate,	washed	with	
saturated	 aqueous	 sodium	 bicarbonate	 and	 brine.	 The	 organic	 layer	 was	 dried	 with	
sodium	 sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 The	 residue	 was	
purified	by	 flash	 column	chromatography	 (hexane:	 ethyl	 acetate	2:	1)	 to	 give	48	 as	 a	
white	solid	(420	mg,	88%).	[α]23D 	 =	+	28.6°	(c	=	0.6,	dichloromethane).	Rf	(hexane:	ethyl	
acetate	1:1)	0.71.	ESI-HRMS:	m/z	calcd	for	C112H115N5NaO24	[M+Na]+	1937.7863,	found	
1937.7868.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	




0.05	 mmol)	 in	 tetrahydrofuran	 (0.5	 mL)	 was	 cooled	 to	 -20	 °C,	 and	 treated	 with	







and	 the	 organic	 layer	was	washed	with	 brine,	 dried	with	 sodium	 sulfate,	 filtered	 and	
concentrated	 under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	
(chloroform:	ethyl	acetate	5:1)	gave	49	as	colorless	oil	(38	mg,	42%).	[α]23D 	 =	+	17.5°	(c	
=	0.9,	dichloromethene).	Rf	(chloroform:	ethyl	acetate	5:1)	0.18.	ESI-HRMS:	m/z	 calcd	






The	 mixture	 was	 filtered,	 concentrated	 under	 reduced	 pressure	 and	 purified	 by	
Sephadex	 C-25	 column	 chromatography	 (gradient	 elution	 of	 0.1%	 -	 1.0%	 ammonium	
hydroxide	in	deionized	water).	The	product-containing	fractions	were	combined,	glacial	
acetic	acid	(40	μL,	0.69	mmol)	was	added,	and	the	mixture	was	freeze	dried	to	give	41	
as	 a	white	 solid	 (5	mg,	 50%	 as	 pentaacetate	 salt)	 with	 spectral	 data	 identical	 to	 the	
above	sample.	 	






mmol)	 and	methanol	 (50	mL)	was	 added.	 The	 reaction	mixture	was	 stirred	 at	 room	
temperature	 for	 18	 h.	 Then	 the	mixture	 was	 cooled	 to	 0	 °C,	 followed	 by	 addition	 of	
imidazolesulfonyl	azide	hydrochloride	salt	(8.4	g,	40	mmol),	potassium	carbonate	(5.6	g,	
40	 mmol)	 and	 copper(II)	 sulfate	pentahydrate	 (125	 mg,	 0.5	 mmol).	 After	 stirring	 at	
room	temperature	for	another	24	h,	0.5	M	hydrochloric	acid	was	added	slowly	into	the	
reaction	mixture	 at	 0	 oC	 until	 pH	 ≈	 3.	 Then	 the	 solution	 was	 saturated	 with	 sodium	
chloride	and	extracted	by	ethyl	acetate	twice.	The	organic	layer	was	washed	with	brine,	
dried	 with	 sodium	 sulfate,	 filtrated	 and	 concentrated	 under	 reduced	 pressure.	 Flash	








J2’-1’	=	10.3	Hz,	 J2’-3’	=	3.7	Hz,	H2’),	2.09	(dt,	 J2eq-2ax	=	12.6	Hz,	 J2eq-1	=	 J2eq-3	=	4.2	Hz,	1H,	
H2eq),	 1.25	–	1.17	 (m,	1H,	H2ax).	 13C	NMR	 (151	MHz,	CD3OD)	δ	157.7	 (-NCO),	128.2,	
127.7,	127.2,	106.9	 (C1’’),	96.6	 (C1’),	83.4	 (C5),	83.0	 (C4’’),	75.6	 (C2’’),	75.4	 (C6),	75.0	




(C5’’),	 60.3	 (C1),	 59.9	 (C3),	 41.6	 (C6’),	 31.7	 (C2).	 ESI-HRMS:	 m/z	 calcd	 for	
C25H34N10NaO12	[M+Na]+	689.2255,	found	689.2255.	
6’-N-Benzyloxycarbonyl-4’-O-6’-N-benzylidene-2’’,3’’-O-benzylidene-1,3,2’-tridea
mino-1,3,2’-triazido	 ribostamycin	 (54)	 Compound	 53	 (500	 mg,	 0.75	 mmol)	 was	
dissolved	in	freshly	distilled	benzaldehyde	(10	mL).	The	mixture	was	cooled	to	0	°C	and	
boron	 trifluoride	 diethyl	 etherate	 (0.2	mL,	 1.6	mmol)	was	 added	drop-wise	 under	 an	
argon	atmosphere.	Reaction	mixture	was	stirred	at	0	°C	for	1.5	h	before	work	up.	The	
mixture	 was	 added	 into	 ice-cold	 saturated	 aqueous	 sodium	 bicarbonate	 slowly	 with	
stirring,	and	 then	extracted	with	ethyl	acetate	 twice.	The	combined	organic	 layer	was	
washed	with	brine	 and	dried	with	 sodium	sulfate.	 Filtration	 and	 concentration	under	



















benzylidene-1,3,2’-trideamino-1,3,2’-triazido	 ribostamycin	 (55)	 Under	 an	 argon	
atmosphere,	 a	 soln.	 of	 54	 (320	 mg,	 0.38	 mmol)	 in	 dry	 tetrahydrofuran	 (6	 mL)	 was	
cooled	to	0	oC.	Sodium	hydride	(60%	in	mineral	oil,	64	mg,	1.6	mmol),	benzyl	bromide	





pressure	 and	 purified	 by	 flash	 column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	











H1,	H3),	3.18	–	3.10	 (m,	2H,	H2’,	H6),	2.93	–	2.78	 (m,	1H,	H6’ax),	2.34	–	2.22	 (m,	1H,	
H2eq),	 1.55	 –	 1.31	 (m,	 1H,	H2ax).	 13C	NMR	 (151	MHz,	 chloroform-d)	 δ	 155.2	 (-NCO),	
138.2	-	135.5	(aromatic),	129.5	-	126.6	(aromatic),	110.2	(C1’),	104.0	(OO-benzylidene)	,	





no-1,3,2’-triazido	 ribostamycin	 (56)	 Compound	 55	 (600	 mg,	 0.54	 mmol)	 was	




concentrated	 under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	
(hexane:	ethyl	acetate	4:	1)	provided	56	as	colorless	oil	(390	mg,	71%).	[α]23D 	 =	+	34.1°	
(c	 =	 0.3,	 dichloromethane).	 Rf	 (hexane:	 ethyl	 acetate	 4:	 1)	 0.36.	 1H	 NMR	 (600	 MHz,	











157.9	 (-NCO),	 138.3	 -	 135.9	 (aromatic),	 128.6	 -	 127.6	 (aromatic),	 109.9	 (C1’’),	 104.1	
(OO-benzylidene),	 96.6	 (C1’),	 84.3	 (C2’’),	 83.8	 (C4’’),	 83.3	 (C6),	 81.4	 (C5),	 81.0	 (C3’’),	
78.9	(C3’),	76.6	(C4),	75.6	(-CH2Ph),	75.4	(-CH2Ph),	73.3	(-CH2Ph),	71.6	(C5’),	71.2	(C4’),	










acetate,	 washed	 with	 water	 and	 brine.	 The	 combined	 organic	 layer	 was	 dried	 with	
sodium	 sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 The	 residue	 was	
purified	by	flash	column	chromatography	over	silica	gel	(hexane:	ethyl	acetate	1:	1)	and	












sodium	 bicarbonate.	 The	 mixture	 was	 extracted	 with	 ethyl	 acetate.	 The	 combined	
organic	 layer	 was	 washed	 with	 brine,	 dried	 with	 sodium	 sulfate,	 filtered	 and	
concentrated	 under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	
(hexane:	ethyl	acetate	3:	2)	gave	58	as	a	white	solid	(150	mg,	66%).	[α]23D 	 =	+	17.8°	(c	=	












and	 the	mixture	was	 brought	 to	 0	 oC	 and	 stirred	 for	 another	 2	 h.	 Saturated	 aqueous	
sodium	bicarbonate	was	added	at	0	oC	and	the	mixture	was	extracted	with	ethyl	acetate.	
The	combined	organic	layer	was	washed	with	brine,	dried	with	sodium	sulfate,	filtered,	
and	 concentrated	 under	 reduced	 pressure.	 The	 residue	was	 purified	 by	 flash	 column	
chromatography	 over	 silica	 gel	 (chloroform:	 ethyl	 acetate	 3:	 1)	 to	 give	59	 as	 a	white	
solid	 (72.4	mg,	32%).	 [a]23D 	 =	+	8.7°	 (c	=	1.7,	dichloromethane).	Rf	(chloroform:	ethyl	
acetate	3:	1)	0.22.	ESI-HRMS:	m/z	 calcd	 for	C70H74N4NaO17	 [M+Na]+	1265.4947,	 found	
1265.4950.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	
characterization.	 The	 presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	
NMR	spectrum	uninterpretable.	 	
3’-Deoxy	 ribostamycin	 (52)190	 A	 soln.	 of	 59	 (35	 mg,	 0.03	 mmol)	 in	 a	 mixture	 of	
1,4-dioxane/water/acetic	acid	1/2/0.2	(0.35	mL)	was	treated	with	palladium	hydroxide	
on	carbon	(35	mg)	under	hydrogen	atmosphere	(48	psi)	at	room	temperature	for	22	h.	
The	 mixture	 was	 filtered,	 concentrated	 under	 reduced	 pressure	 and	 purified	 by	
Sephadex	 C-25	 column	 chromatography	 (gradient	 elution	 of	 0.1%	 -	 1.0%	 ammonium	












=	 J3’ax-2’	=	 J3’ax-4’	=	11.7	Hz,	1H,	H3’ax),	1.72	(s,	12H,	CH3CO2H),	1.62	(q,	 J2ax-2eq	=	 J2ax-1	=	
J2ax-3	 =	12.6	Hz,	 1H,	H2ax).	 13C	NMR	 (151	MHz,	D2O)	 δ	180.8	 (CH3CO2H),	 110.3	 (C1’’),	
93.4	(C1’),	84.9	(C5),	82.4	(C4’’),	75.8	(C6),	75.1	(C5’),	72.4	(C4),	70.0	(C2’’),	69.0	(C3’’),	
64.5	(C4’),	60.9	(C5’’),	49.8	(C1),	48.4	(C3),	47.7	(C2’),	39.8	(C6’),	29.1	(C3’),	28.6	(C2),	





at	 70	 oC	 for	 1	 h.	 Then	0.1	M	 sodium	hydroxide	 solution	 (6.5	mL)	was	 added	 and	 the	
mixture	was	heated	at	70	oC	 for	8	h.	N-(Benzyloxycarbonyloxy)succinimide	(2.0	g,	8.0	
mmol)	and	potassium	carbonate	(1.2	g,	8.7	mmol)	were	added	and	the	reaction	mixture	
was	 stirred	 at	 room	 temperature	 for	 24	 h.	 The	 reaction	mixture	 was	 extracted	 with	
ethyl	acetate	and	the	separated	organic	 layer	was	washed	with	1	M	hydrochloric	acid	
and	brine.	After	drying	with	sodium	sulfate,	filtration	and	concentration	under	reduced	
pressure,	 the	 residue	 was	 purified	 by	 flash	 column	 chromatography	 over	 silica	 gel	
(hexane:	ethyl	acetate	1:	1)	and	provided	62	as	a	white	solid	(1.08	g,	85%).	[α]23D 	 =	+	








o	 neomycin	 (63)	A	soln.	of	62	 (1.05	g,	0.54	mmol)	 in	dichloromethane	 (20	mL)	was	
treated	 with	 Dess-Martin	 periodinane	 (460	 mg,	 1.08	 mmol)	 and	 stirred	 at	 room	
temperature	 for	 24	 h.	 The	 reaction	 was	 quenched	 by	 addition	 of	 saturated	 aqueous	
sodium	bicarbonate	and	then	extracted	with	ethyl	acetate.	The	separated	organic	layer	
was	washed	with	water	and	brine,	dried	with	sodium	sulfate,	filtered	and	concentrated	
under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	
acetate	 2:	 1)	 gave	 63	 as	 a	 white	 solid	 (830	 mg,	 79%)	 [α]23D 	 =	 +	 20.2°	 (c	 =	 1.1,	
dichloromethane).	 Rf	 (hexane:	 ethyl	 acetate	 1:	 1)	 0.45.	 ESI-HRMS:	 m/z	 calcd	 for	
C113H116N6NaO25	[M+Na]+	1980.7921,	found	1980.7920.	This	compound	was	employed	
















m/z	 calcd	 for	 C106H112N6NaO24	 [M+Na]+	1876.7659,	 found	 1876.7657.	 This	 compound	
was	 employed	 in	 the	 next	 step	 without	 further	 characterization.	 The	 presence	 of	
rotamers	in	the	multiple	Cbz	groups	rendered	the	NMR	spectrum	uninterpretable.	 	
3’-Deoxy	neomycin	 (60)191	A	soln.	of	64	 (80	mg,	0.04	mmol)	 in	dioxane	(1	mL)	was	
mixed	with	palladium	hydroxide	on	carbon	 (40	mg)	and	stirred	at	 room	 temperature	
under	 a	 hydrogen	 atmosphere	 (40	 psi)	 for	 12	 h.	 Deionized	water	 (2	mL)	 and	 glacial	
acetic	acid	 (0.2	mL)	was	added	and	 the	mixture	was	kept	stirring	 for	another	12	h	at	
room	 temperature	 under	 a	 hydrogen	 atmosphere	 (40	 psi).	 After	 filtration	 through	 a	
Celite	 pad,	 the	 cake	was	washed	with	deionized	water	 and	 the	 filtrate	was	 combined	
and	concentrated	under	reduced	pressure.	The	residue	was	purified	by	Sephadex	C-25	
column	 chromatography	 (gradient	 elution	 of	 0.1%	 -	 1.0%	 ammonium	 hydroxide	 in	
deionized	 water),	 and	 the	 product-containing	 fractions	 were	 combined	 and	 glacial	
acetic	 acid	 (40	 μL,	 0.7	mmol)	was	 added.	 Lyophilization	 of	 the	mixture	 gave	60	 as	 a	











Hz,	1H,	H2eq),	2.07	 (dt,	 J3’eq-3’ax	=	12.0	Hz,	 J3’eq-2’	 =	 J3’eq-4’	 =	4.2	Hz,	1H,	H3’eq),	1.84	 (q,	
J3’ax-3’eq	 =	 J3’ax-2’	 =	 J3’ax-4’	 =	 12.0	 Hz,	 1H,	 H3’ax),	 1.75	 (s,	 18H	 CH3CO2H),	 1.71	 –	 1.62	 (q,	
J2ax-2eq	=	J2ax-1	=	J2ax-3	=	11.7	Hz,	1H,	H2ax).	13C	NMR	(151	MHz,	cdcl3)	δ	180.6	(CH3CO2H),	
109.8	 (C1’’),	 96.0	 (C1’’’),	 93.0	 (C1’),	 84.5	 (C5),	 81.1	 (C4’’),	 75.1	 (C4),	 75.0	 (C3’’),	 73.3	
(C2’’),	71.9	(C6),	69.8	(C5’),	69.7	(C5’’’),	67.1	(C3’’’),	66.9	(C4’’’),	64.4	(C4’),	60.1	(C5’’),	
50.2	(C2’’’),	49.4	(C1),	48.2	(C3),	47.5	(C2’),	39.9	(C6’’’),	39.7	(C6’),	28.7	(C3’),	27.8	(C2),	
22.1	 (CH3CO2H).	 ESI-HRMS:	 m/z	 calcd	 for	 C23H47N6O12	 [M+H]+	 599.3246,	 found	
599.3241.	
61,3,2’,2’’’,6’’’-Pentadeamino-1,3,2’,2’’’,6’’’-pentaazido-4’,6’-O-benzylidene-5’’-O-tri
isopropylsilyl	 paromomycin	 (79)	 A	 soln.	 of	 78	 (4.16	 g,	 5	 mmol)	 in	 dry	
dichloromethane	 (80	 mL)	 was	 treated	 with	 2,6-lutidine	 (3.07	 mL,	 25	 mmol)	 and	
triisopropylsilyl	 trifluoromethanesulfonate	 (1.51	 mL,	 6	 mmol)	 and	 stirred	 at	 room	
temperature	for	1.5	h.	The	reaction	mixture	was	diluted	with	ethyl	acetate,	washed	with	
saturated	 aqueous	 sodium	 bicarbonate	 and	 brine.	 The	 organic	 layer	 was	 dried	 with	






ethyl	 acetate	 1:	 4)	 0.45.	 1H	 NMR	 (600	 MHz,	 chloroform-d)	 δ	 7.51	 –	 7.47	 (m,	 2H,	









136.9	 (aromatic),	 129.5	 (aromatic),	 128.5	 (aromatic),	 126.4	 (aromatic),	 106.3	 (C1’’),	
102.1	 (benzylidene	 C),	 99.0	 (C1’’’),	 97.9	 (C1’),	 84.6	 (C4),	 83.6	 (C2’’),	 81.5	 (C4’),	 77.0	
(C3’’),	76.4	 (C4’’’),	75.1	 (C5),	75.0	 (C4’’),	74.0	 (C5’’’),	69.2	 (C3’’’),	69.0	 (C6),	68.8	 (C6’),	
68.5	(C3’),	63.7	(C2’),	63.2	(C5’’),	62.8	(C5’),	60.8	(C2’’’),	59.4	(C3),	59.2	(C1),	51.2	(C6’),	









stirring	 followed	 by	 addition	 of	 benzyl	 bromide	 (4	 mL,	 31.8	 mmol)	 and	
tetrabutylammonium	iodide	(148	mg,	0.4	mmol).	The	reaction	mixture	was	warmed	up	
to	 room	 temperature	 and	 stirred	 for	 15	 h	 under	 argon	 atmosphere.	 Methanol	 was	
added	to	quench	the	reaction	at	0	oC,	and	then	saturated	aqueous	sodium	bicarbonate	
was	 added.	 The	mixture	 was	 extracted	 with	 ethyl	 acetate	 and	 the	 combined	 organic	
layer	 was	 washed	 with	 brine,	 dried	 with	 sodium	 sulfate,	 filtered	 and	 concentrated	
under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	


















MHz,	 chloroform-d)	δ	138.1	 -	137.0	 (aromatic),	129.0	 -	126.1	 (aromatic),	107.2	 (C1’’),	
101.4	(benzylidene-H),	98.3	(C1’’’),	96.7	(C1’),	83.2	(C4’’),	83.2	(C6),	82.4	(C4’),	82.3	(C5),	
81.3	 (C2’’),	76.6	 (C4),	76.5	 (C3’),	74.9	 (C3’’),	74.8	 (-CH2Ph),	74.7	 (-CH2Ph),	73.8	 (C5’’’),	
73.0	 (C3’’’),	 72.6	 (-CH2Ph),	 72.5	 (-CH2Ph),	 71.8	 (-CH2Ph),	 71.6	 (C4’’’),	 69.0	 (C6’),	 64.0	
(C5’’),	63.2	(C2’),	62.9	(C5’),	60.4	(C3),	59.4	(C1),	57.6	(C2’’’),	51.0	(C6’’’),	32.0	(C2),	18.1	




tetrahydrofuran	 (42	 mL)	 was	 treated	 with	 trimethylphosphine	 solution	 (1	 M	 in	
tetrahydrofuran,	23.3	mL,	23.3	mmol)	at	65	°C	for	1	h.	Sodium	hydroxide	solution	(0.1	
M	in	water,	42	mL)	was	added	and	the	mixture	was	kept	stirring	at	65	°C	for	another	3	h.	
The	 reaction	 mixture	 was	 cooled	 to	 room	 temperature,	 and	 then	
N-(benzyloxycarbonyloxy)succinimide	 (7.27	 g,	 29.2	 mmol)	 and	 potassium	 carbonate	
(4.03	g,	29.2	mmol)	were	added.	After	stirring	at	room	temperature	for	15	h,	saturated	
aqueous	 sodium	 bicarbonate	 was	 added,	 and	 the	 mixture	 was	 extracted	 with	 ethyl	
acetate.	The	combined	organic	layer	was	washed	with	brine,	dried	with	sodium	sulfate,	
filtered	 and	 concentrated	 under	 reduced	 pressure.	 The	 residue	was	 purified	 by	 flash	





acetate	 2:	 1)	 0.25.	 ESI-HRMS:	m/z	 calcd	 for	 C114H129N5NaO24Si	 [M+Na]+	 2003.8728,	
found	 2003.8725.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	




2	mL)	was	added	 into	a	soln.	of	81	 (1.98	g,	1	mmol)	 in	 tetrahydrofuran	(20	mL).	The	
reaction	mixture	was	stirred	at	room	temperature	for	1	h,	and	then	diluted	with	ethyl	
acetate.	The	mixture	was	washed	with	saturated	sodium	aqueous	bicarbonate	and	brine,	
dried	 with	 sodium	 sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 Flash	
column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	 acetate	 1:	 1)	 afforded	82	 as	 a	
white	solid	(1.21	g,	66%).	[α]23D 	 =	+	9.2°	(c	=	0.7,	dichloromethane).	Rf	(hexane:	ethyl	
acetate	1:	1)	0.32.	ESI-HRMS:	m/z	calcd	for	C105H109N5NaO24	[M+Na]+	1847.7394,	found	
1847.7396.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	




dichloromethane	 (12	 mL)	 was	 treated	 with	 p-toluenesulfonyl	 chloride	 (1.28	 g,	 6.6	
mmol),	 triethylamine	(1.8	mL,	13.2	mmol)	and	4-dimethylaminopyridine	(80	mg,	0.66	




ethyl	 acetate,	 washed	 sequentially	 with	 saturated	 aqueous	 sodium	 bicarbonate,	 1	 M	
hydrochloric	acid	and	brine.	The	organic	 layer	was	dried	with	sodium	sulfate,	 filtered	
and	 concentrated	 under	 reduced	 pressure.	 The	 residue	 was	 dissolved	 in	 dry	
dimethylformamide	 (12	 mL)	 and	 sodium	 azide	 (430	 mg,	 6.6	 mmol)	 was	 added.	 The	
reaction	mixture	was	stirred	at	65	°C	for	15	h,	and	then	cooled	to	room	temperature	and	
diluted	 with	 ethyl	 acetate.	 The	 mixture	 was	 washed	 with	 saturated	 sodium	 aqueous	
bicarbonate	and	brine,	and	the	organic	layer	was	dried	with	sodium	sulfate,	filtered	and	




This	 compound	was	 employed	 in	 the	 next	 step	without	 further	 characterization.	 The	
presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	 NMR	 spectrum	
uninterpretable.	 	 	
6,3’,2’’,3’’’,4’’’-Penta-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-4’,6’-O-be
nzylidene-5’’-deoxy-5’’-formamido	 paromomycin	 (84)	 Compound	83	 (1.57	 g,	 0.85	
mmol)	was	dissolved	in	tetrahydrofuran	(16	mL)	and	treated	with	trimethylphosphine	
(1	M	in	tetrahydrofuran,	1.7	mL,	1.7	mmol)	at	65	°C	for	1	h.	Deionized	water	(16	mL)	
was	 added	 and	 the	 mixture	 was	 heated	 at	 65	 °C	 for	 another	 3	 h.	 The	 solvent	 was	
removed	 under	 reduced	 pressure,	 and	 then	 the	 residue	 was	 dissolved	 in	









This	 compound	was	 employed	 in	 the	 next	 step	without	 further	 characterization.	 The	
presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	 NMR	 spectrum	
uninterpretable.	 	 	
6,3’,6’,2’’,3’’’,4’’’-Hexa-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-5’’-deoxy
-5’’-formamido	 paromomycin	 (85)	 A	 soln.	 of	 84	 (1.06	 g,	 0.57	 mmol)	 in	 dry	
tetrahydrofuran	 (10	mL)	was	 stirred	with	activated	4	Å	molecular	 sieves	and	sodium	
cyanoborohydride	 (730	 mg,	 11.5	 mmol)	 at	 room	 temperature	 under	 an	 argon	
atmosphere	 for	 1	 h.	 The	 mixture	 was	 cooled	 to	 0	 °C	 and	 2	 M	 hydrogen	 chloride	 in	
diethyl	 ether	 soln.	 (11.5	mL,	 23	mmol)	was	 added	drop-wise.	 After	 stirring	 under	 an	
argon	atmosphere	at	0	oC	for	2	h,	the	reaction	mixture	was	added	into	ice-cold	saturated	
aqueous	 sodium	 bicarbonate	 slowly	 and	 then	 extracted	 with	 ethyl	 acetate.	 The	
combined	organic	layer	was	washed	with	brine,	dried	with	sodium	sulfate,	filtered,	and	
concentrated	 under	 reduced	 pressure.	 Flash	 column	 chromatography	 over	 silica	 gel	
(hexane:	ethyl	acetate	1:	2)	gave	85	as	a	white	solid	(804	mg,	75%).	[α]23D 	 =	+	8.1°	(c	=	





in	 the	 next	 step	 without	 further	 characterization.	 The	 presence	 of	 rotamers	 in	 the	
multiple	Cbz	groups	rendered	the	NMR	spectrum	uninterpretable.	 	 	
6,3’,6’,2’’,3’’’,4’’’-Hexa-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-5’’-deoxy
-5’’-formamido-4’-keto	 paromomycin	 (86)	 Dess-Martin	 periodinane	 (276	mg,	 0.65	
mmol)	was	added	 into	a	soln.	of	85	 (804	mg,	0.43	mmol)	 in	dichloromethane	(8	mL).	
The	 mixture	 was	 stirred	 at	 room	 temperature	 for	 7	 h,	 and	 then	 diluted	 with	 ethyl	
acetate,	 washed	 with	 saturated	 sodium	 aqueous	 bicarbonate	 and	 brine.	 The	 organic	
layer	was	dried	with	sodium	sulfate,	filtered	and	concentrated	under	reduced	pressure.	
The	residue	was	purified	by	flash	column	chromatography	over	silica	gel	(hexane:	ethyl	
acetate	 1:	 1)	 to	 give	 86	 as	 a	 white	 solid	 (574	 mg,	 72%).	 [α]23D 	 =	 +	 19.3°	 (c	 =	 0.9,	
dichloromethane).	 Rf	 (hexane:	 ethyl	 acetate	 1:	 2)	 0.45.	 ESI-HRMS:	 m/z	 calcd	 for	
C106H110N6NaO24	[M+Na]+	1874.7503,	found	1874.7505.	This	compound	was	employed	
in	 the	 next	 step	 without	 further	 characterization.	 The	 presence	 of	 rotamers	 in	 the	
multiple	Cbz	groups	rendered	the	NMR	spectrum	uninterpretable.	 	 	
6,6’,2’’,3’’’,4’’’-Penta-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-3’,5’’-dide












11.6°	 (c	 =	 1.3,	 dichloromethane).	Rf	 (hexane:	 ethyl	 acetate	1:	 4)	 0.55.	 ESI-HRMS:	m/z	






hydrogen	atmosphere	 (48	psi)	 for	24	h.	After	 filtration	 through	a	Celite	pad,	 the	cake	
was	 washed	 with	 deionized	 water	 and	 the	 filtrate	 was	 combined	 and	 concentrated	
under	 reduced	 pressure.	 The	 residue	 was	 purified	 by	 Sephadex	 C-25	 column	
chromatography	 (gradient	 elution	 of	 0.1%	 -	 1.0%	ammonium	hydroxide	 in	 deionized	










(m,	 1H,	 H2eq),	 2.09	 –	 2.05	 (m,	 1H,	 H3’eq),	 1.88	 –	 1,84	 (m,	 1H,	 H3’ax),	 1.79	 (s,	 15H,	
CH3CO2H),	1.66	–	1.62	(m,	1H,	H2ax).	13C	NMR	(150	MHz,	D2O)	δ	180.3	(CH3COOH),	164.8	
(CHO),	109.9	(C1’’),	95.5	(C1’),	95.4	(C1’’’),	83.2	(C5),	79.4	(C4’’),	77.2	(C4),	74.1	(C5’),	






dissolved	 in	 dry	 dichloromethane	 (15	 mL)	 and	 treated	 with	 borane	 trimethylamine	
(150	mg,	2	mmol),	 freshly	dried	copper(II)	 triflate	(18	mg,	0.05	mmol)	and	a	catalytic	
amount	 of	 triflic	 acid	 (0.1	 mL)	 under	 argon	 atmosphere.	 After	 stirring	 at	 room	
temperature	 for	 2	 h,	 the	 reaction	 was	 quenched	 by	 adding	 into	 ice-cold	 saturated	
aqueous	sodium	bicarbonate	slowly.	The	mixture	was	extracted	with	ethyl	acetate,	and	
the	 organic	 layer	 was	 washed	 with	 brine	 and	 dried	 with	 sodium	 sulfate.	 Filtration,	














0.97	 (m,	 21H,	 -Si(CH(CH3)2)3).	 13C	 NMR	 (101	 MHz,	 chloroform-d)	 δ	 138.26	 -	 137.06	
(aromatic),	 128.69	 -	 127.48	 (aromatic),	 106.72	 (C1’’),	 98.51	 (C1’’),	 96.33	 (C1’),	 83.50	
(C4’’),	83.23	(C6)	 ,	82.15	(C5),	81.59	(C2’’),	79.77	(C3’),	75.86	(C4),	75.03	(C3’’),	74.87	






sopropylsilyl	 paromomycin	 (89)	 A	 soln.	 of	 88	 (250	 mg,	 0.17	 mmol)	 in	
tetrahydrofuran	 (5	 mL)	 was	 heated	 at	 70	 oC	 with	 trimethylphosphine	 (1	 M	 in	
tetrahydrofuran,	1.4	mL,	1.4	mmol)	 for	1	h,	and	 then	0.1	M	sodium	hydroxide	 (5	mL)	










a	white	 solid	 (265	mg,	79%).	 [α]23D 	 =	+	17.6°	 (c	 =	1.4,	 dichloromethane).	Rf	 (hexane:	
ethyl	acetate	1:	1)	0.60.	ESI-HRMS:	m/z	calcd	for	C114H131N5NaO24Si	[M+Na]+	2005.8885,	
found	 2005.8888.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	
characterization.	 The	 presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	
NMR	spectrum	uninterpretable.	 	 	
6,3’,6’,2’’,3’’’,4’’’-Hexa-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-5’’-O-trii
sopropylsilyl-4’-keto	 paromomycin	 (90)	 Compound	 89	 (265	 mg,	 0.13	 mmol)	 was	
dissolved	 in	 dichloromethane	 (5	mL)	 and	 treated	with	Dess-Martin	 periodinane	 (114	
mg,	 0.26	 mmol).	 The	 mixture	 was	 stirred	 at	 room	 temperature	 for	 20	 h.	 Saturated	




a	white	 solid	 (192	mg,	75%).	 [α]23D 	 =	+	38.6°	 (c	 =	0.8,	 dichloromethane).	Rf	 (hexane:	
ethyl	acetate	1:	1)	0.55.	ESI-HRMS:	m/z	calcd	for	C114H129N5NaO24Si	[M+Na]+	2003.8728,	
found	 2003.8723.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	










stirred	 under	 an	 argon	 atmosphere	 for	 1.5	 h.	 Saturated	 aqueous	 sodium	 bicarbonate	
was	 added	 at	 0	 oC	 to	 quench	 the	 reaction	 and	 the	mixture	 was	 extracted	 with	 ethyl	
acetate.	 The	 organic	 layer	was	washed	with	 brine,	 dried	with	 sodium	 sulfate,	 filtered	
and	 concentrated	 under	 reduced	 pressure.	 The	 residue	was	 purified	 by	 flash	 column	
chromatography	over	silica	gel	(hexane:	ethyl	acetate	3:	1)	to	give	91	as	a	colorless	oil	
(171	mg,	36%).	[α]23D 	 =	+	27.6°	(c	=	1.0,	dichloromethane).	Rf	(hexane:	ethyl	acetate	1:	
1)	 0.25.	 ESI-HRMS:	 m/z	 calcd	 for	 C107H125N5NaO23Si	 [M+Na]+	 1899.8466,	 found	
1899.8469.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	
characterization.	 The	 presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	
NMR	spectrum	uninterpretable.	 	 	
6,6’,2’’,3’’’,4’’’-Penta-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-3’-deoxy	








column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	 acetate	 1:	 1)	 afforded	92	 as	 a	
white	solid	(100	mg,	65%).	[α]23D 	 =	+	8.8°	(c	=	0.6,	dichloromethane).	Rf	(hexane:	ethyl	
acetate	1:	2)	0.45.	ESI-HRMS:	m/z	calcd	for	C98H105N5NaO23	[M+Na]+	1743.7132,	found	
1743.7133.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	
characterization.	 The	 presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	
NMR	spectrum	uninterpretable.	 	 	
6,6’,2’’,3’’’,4’’’-Penta-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-benzyloxycarbonyl-3’-deoxy-5
’’-O-tosyl	 paromomycin	 (93)	 Compound	 92	 (240	 mg,	 0.14	 mmol)	 was	 dissolved	
dichloromethane	 (5	mL).	 Pyridine	 (112	μL,	 1.4	mmol)	 and	p-toluenesulfonyl	 chloride	
(267	mg,	1.4	mmol)	were	added	and	the	mixture	was	stirred	at	room	temperature	for	




0.6,	 dichloromethane).	Rf	 (hexane:	 ethyl	 acetate	 1:	 1)	 0.27.	 ESI-HRMS:	m/z	 calcd	 for	
C105H111N5NaO25S	[M+Na]+	1897.7220,	found	1897.7723.	This	compound	was	employed	








for	 2	 h.	 The	 solvent	 was	 removed	 under	 reduced	 pressure	 and	 the	 residue	 was	
dissolved	 in	 dry	 dimethylformamide	 (2	mL).	 Lithium	 azide	 (160	mg,	 3.3	 mmol)	 was	
added	 and	 the	 mixture	 was	 heated	 at	 65	 oC	 for	 2	 h.	 After	 cooling	 down	 to	 room	
temperature,	the	reaction	mixture	was	diluted	with	ethyl	acetate,	and	then	washed	with	
1	M	hydrochloric	acid	twice.	The	organic	 layer	was	washed	with	brine	and	dried	with	
sodium	 sulfate.	 Filtration,	 concentration	 under	 reduced	 pressure	 and	 purification	 by	
flash	column	chromatography	over	silica	gel	(hexane:	ethyl	acetate	1:	1)	afforded	94	as	
a	colorless	oil	 (145	mg,	75%).	 [α]23D 	 =	+	16.0°	(c	=	0.4,	dichloromethane).	Rf	(hexane:	
ethyl	acetate	1:	1)	0.16.	ESI-HRMS:	m/z	 calcd	 for	C98H104N8NaO22	 [M+Na]+	1768.7196,	
found	 1768.7195.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	






mL)	was	 added.	 After	 stirring	 at	 65	 oC	 for	 7	 h,	 the	mixture	was	 extracted	with	 ethyl	
acetate.	 The	 organic	 layer	was	washed	with	 brine,	 dried	with	 sodium	 sulfate,	 filtered	
and	 concentrated	 under	 reduced	 pressure.	 The	 residue	 was	 dissolved	 in	
dichloromethane	 (1	 mL)	 and	 freshly	 prepared	 formic	 acetic	 anhydride	 (1	 mL)	 was	




dryness	 under	 reduced	 pressure.	 The	 residue	 was	 purified	 by	 flash	 column	
chromatography	over	silica	gel	(hexane:	ethyl	acetate	1:	3)	to	afford	87	as	a	white	solid	
(36	mg,	73%),	with	physical	data	identical	to	the	previously	described	sample.	
1,6-Anhydro-2,4-O-ditosyl-β-D-glucopyranose	 (112)192	 A	 soln.	 of	 111	 (4.9	 g,	 30	
mmol)	 in	 a	 mixture	 of	 acetone/pyridine	 (1:	 1,	 96	 mL)	 was	 treated	 with	
p-toluenesulfonyl	chloride	(13.3	g,	70	mmol)	at	0	oC.	The	mixture	was	slowly	warmed	
up	to	room	temperature	and	kept	stirring	for	16	h.	The	solvent	was	evaporated	under	




1,6-Anhydro-3,4-epoxy-2-tosyl-β-D-glucopyranose	 (113)192	 Compound	 112	 (12	 g,	
25.5	mmol)	was	dissolved	in	a	mixture	of	methanol/dichloromethane	(1:	2,	60	mL)	and	
sodium	methoxide	 (4.25	 g,	 78.7	mmol)	was	 added	 at	 0	 oC.	 The	 reaction	mixture	was	
slowly	warmed	up	 to	 room	 temperature	and	stirred	 for	2	h.	The	mixture	was	diluted	
with	 dichloromethane	 and	 then	washed	with	water	 and	brine.	 The	 organic	 layer	was	








tetrahydrofuran	 (50	mL)	 slowly	 at	 0	 oC	 under	 an	 argon	 atmosphere.	 After	 stirring	 at	
room	temperature	for	19	h,	the	mixture	was	diluted	with	ethyl	acetate,	washed	with	1	M	
hydrochloric	 acid,	 saturated	 aqueous	 ammonium	 chloride,	 saturated	 aqueous	 sodium	
bicarbonate	 and	 brine.	 The	 organic	 layer	was	 dried	with	 sodium	 sulfate,	 filtered	 and	
concentrated	 under	 reduced	 pressure.	 The	 residue	 was	 purified	 by	 flash	 column	
chromatography	over	silica	gel	(hexane:	ethyl	acetate	2:	1)	to	afford	114	as	light	yellow	
oil	(3.37	g,	49%)	with	data	identical	to	the	literature.193	 	
1,6-Anhydro-4-deoxy-4-C-allyl-2,3-epoxy-β-D-glucopyranose	 (115)194	 A	 soln.	 of	
114	(3.37	g,	9.9	mmol)	in	dry	tetrahydrofuran	(60	mL)	was	cooled	to	0	oC	and	treated	
with	 sodium	 hydride	 (60%	 in	 mineral	 oil,	 793	 mg,	 19.8	 mmol)	 under	 an	 argon	
atmosphere.	The	reaction	mixture	was	stirred	at	room	temperature	for	20	h,	and	then	
cooled	 to	 0	 oC.	 Saturated	 aqueous	 ammonium	 chloride	 was	 added	 to	 quench	 the	

























through	 a	 Celite	 pad	 and	 the	 solid	was	washed	with	methanol.	 The	 combined	 filtrate	
was	concentrated	under	reduced	pressure	and	the	residue	was	dissolved	in	a	mixture	of	
methanol/water	 (3:	 1,	 28	 mL).	 Potassium	 carbonate	 (7.1	 g,	 51.5	 mmol)	 and	 benzyl	
chloroformate	 (2.2	 mL,	 15	 mmol)	 were	 added	 and	 the	 mixture	 was	 stirred	 at	 room	
temperature	 for	 16	 h.	 The	 mixture	 was	 diluted	 with	 ethyl	 acetate,	 washed	 with	
saturated	 aqueous	 sodium	 bicarbonate	 and	 brine.	 The	 organic	 layer	 was	 dried	 with	










CH3CH2CH2),	 1.49	 –	 1.38	 (m,	 2H:	 CH3CH2CH2,	 CH3CH2CH2),	 1.38	 –	 1.26	 (m,	 1H:	





ocarbonyl]-β-D-glucopyranose	 (118)	 A	 soln.	 of	 117	 (1.54	 g,	 4.8	 mmol)	 in	 dry	
tetrahydrofuran	 (40	 mL)	 was	 cooled	 to	 0	 oC	 and	 sequentially	 treated	 with	 sodium	
hydride	(60%	in	mineral	oil,	230	mg,	5.8	mmol)	and	carbon	disulfide	(5.3	mL,	4.8	mmol)	





gel	 (hexane:	 ethyl	 acetate	5:	1)	 to	 give	118	 as	 light	 yellow	oil	 (1.83	g,	 93%).	 [α]23D 	 =	















heated	 with	 tris(trimethylsilyl)silane	 (1.64	mL,	 5.3	 mmol)	 and	 azobisisobutyronitrile	
(215	mg,	1.3	mmol)	at	80	oC	under	an	argon	atmosphere	for	18	h.	The	reaction	mixture	
was	 cooled	 to	 room	 temperature	 and	 tetrabutylammonium	 fluoride	 (1	 M	 in	
tetrahydrofuran,	 13.5	mL,	 13.5	mmol)	was	 added.	After	 stirring	 at	 room	 temperature	
for	0.5	h,	the	mixture	was	diluted	with	diethyl	ether	and	washed	with	water	and	brine.	













(CH3CH2CH2).	 ESI-HRMS:	 m/z	 calcd	 for	 C17H23NO4Na	 [M+Na]+	 328.1525,	 found	
328.1531.	
1,6-Anhydro-2-azido-2,3,4-trideoxy-4-C-propyl-β-D-glucopyranose	 (120)	
Palladium	 on	 carbon	 (1.44	 g)	 was	 added	 into	 a	 soln.	 of	119	 (1.44	 g,	 4.4	mmol)	 in	 a	
mixture	 of	 ethanol/acetic	 acid	 (3:	 0.1,	 15.5	 mL).	 The	 mixture	 was	 stirred	 at	 room	
temperature	under	a	hydrogen	atmosphere	(48	psi)	for	24	h	and	then	filtered	through	a	
Celite	 pad.	 The	 cake	 was	 washed	 with	 ethanol	 and	 the	 combined	 filtrate	 was	
concentrated	 under	 reduced	 pressure.	 The	 residue	 was	 dissolved	 in	 a	 mixture	 of	
methanol/water	 (1:	1,	28	mL).	 Imidazolesulfonyl	 azide	hydrochloride	 salt	 (1.38	g,	6.6	
mmol),	 potassium	 carbonate	 (3.04	 g,	 22	 mmol)	 and	 copper(II)	 sulfate	 pentahydrate	
(110	mg,	 0.44	mmol)	 were	 added	 at	 0	 oC	 and	 the	mixture	 was	 warmed	 up	 to	 room	
temperature	 and	 stirred	 for	 17	 h.	 The	 reaction	mixture	was	 acidified	 by	 adding	 1	M	
hydrochloric	 slowly	until	pH	≈	2-3	at	0	 oC,	 and	 then	extracted	with	ethyl	acetate.	The	
organic	 layer	 was	 washed	 with	 brine	 and	 dried	 with	 sodium	 sulfate.	 Filtration,	









CH3CH2CH2),	 1.53	 –	 1.45	 (m,	 1H:	 H4),	 1.53	 –	 1.45	 (m,	 1H:	 H4),	 1.47	 –	 1.31	 (m,	 2H:	
CH3CH2CH2),	0.95	 (t,	 J	 =	7.3	Hz,	3H:	CH3CH2CH2).	 13C	NMR	(125	MHz,	 chloroform-d)	δ	
100.6	(C1),	76.0	(C5),	68.2	(C6),	57.6	(C2),	36.0	(C4),	34.5	(CH3CH2CH2),	24.2	(C3),	20.8	
(CH3CH2CH2),	 14.0	 (CH3CH2CH2).	 ESI-HRMS:	 m/z	 calcd	 for	 C9H15N3O2Na	 [M+Na]+	
220.1062,	found	220.1056.	
Phenyl	 2-azido-2,3,4-trideoxy-4-C-propyl-1-thio-β-D-glucopyranoside	 (121)	 To	 a	
soln.	 of	120	 (264	mg,	 1.34	mmol)	 in	 1,2-dichloroethane	 (8	mL)	 were	 added	 zinc(II)	
iodide	 (1.27	 g,	 4	 mmol)	 and	 trimethyl(phenylthio)silane	 (0.76	 mL,	 4	 mmol).	 The	
mixture	 was	 stirred	 at	 room	 temperature	 for	 20	 h.	 After	 diluting	 with	
1,2-dichloroethane,	the	mixture	was	filtered	through	a	Celite	pad.	The	solid	was	washed	
with	1,2-dichloroethane	and	the	combined	filtrate	was	washed	with	saturated	aqueous	
sodium	 bicarbonate	 and	 brine,	 dried	 with	 sodium	 sulfate,	 filtered	 and	 concentrated	
under	reduced	pressure.	The	residue	was	dissolved	in	a	mixture	of	methanol/water	(10:	
1,	 11	 mL)	 and	 stirred	 with	 potassium	 carbonate	 (372	 mg,	 2.7	 mmol)	 at	 room	
temperature	for	1	h.	The	mixture	was	diluted	with	ethyl	acetate,	washed	with	brine	and	











(m,	 4H:	 CH3CH2CH2,	 CH3CH2CH2,	 CH3CH2CH2,	 CH3CH2CH2),	 0.94	 (t,	 J	 =	 7.1	 Hz,	 3H:	
CH3CH2CH2).	13C	NMR	(125	MHz,	chloroform-d)	δ	133.6,	132.6,	129.1,	127.7,	88.6	(C1),	





1H:	 HO-C6),	 1.68	 –	 1.58	 (m,	 1H:	 H4),	 1.50	 –	 1.15	 (m,	 5H:	 CH3CH2CH2,	 CH3CH2CH2,	
CH3CH2CH2),	1.12	–	1.00	(m,	1H:	CH3CH2CH2),	0.90	(t,	J	=	7.1	Hz,	1H:	CH3CH2).	13C	NMR	









tetrabutylammonium	 iodide	 (41	mg,	 0.11	mmol)	 at	 0	 oC	 under	 an	 argon	 atmosphere.	
The	mixture	was	allowed	to	warm	up	to	room	temperature	and	stirred	for	16	h.	After	
quenching	by	addition	of	methanol	at	0	oC,	the	reaction	mixture	was	diluted	with	ethyl	




(10:	 1,	 5	 mL).	 A	 soln.	 of	 L-selectfluor	 (242	 mg,	 0.68	 mmol)	 in	 a	 mixture	 of	
acetonitrile/water	 (10:	 1,	 5	mL)	 and	 sodium	 bicarbonate	 (240	mg,	 2.85	mmol)	were	
added.	After	stirring	at	room	temperature	for	1.5	h,	the	mixture	was	concentrated	under	
reduced	 pressure.	 The	 residue	 was	 dissolved	 in	 dichloromethane	 and	 washed	 with	
saturated	aqueous	sodium	bicarbonate/water	 (1:	9)	and	brine.	The	organic	 layer	was	
dried	 with	 sodium	 sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 Flash	
column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	 acetate	 2:	 1)	 afforded	 123	 as	
colorless	 oil	 (192	mg,	 73%)	 and	 an	 inseparable	 anomeric	mixtures,	which	 are	 also	 a	
mixture	of	diastereomers	at	sulfur.	Rf	(hexane:	ethyl	acetate	3:	1)	0.17.	ESI-HRMS:	m/z	











mixture	 was	 extracted	 with	 ethyl	 acetate	 and	 the	 organic	 layer	 was	 washed	 with	
saturated	 aqueous	 sodium	 bicarbonate	 and	 brine	 and	 dried	 with	 sodium	 sulfate.	
Filtration,	 concentration	 under	 reduced	 pressure	 and	 purification	 by	 flash	 column	


















83.5	 (C6),	 83.3	 (C4’’),	 82.4	 (C5),	 81.5	 (C2’’),	 79.9	 (C3’),	 75.9	 (C4),	 74.9	 (C3’’),	 74.8	
(-CH2Ph),	 73.7	 (-CH2Ph),	 73.1	 (C5’’’),	 72.7	 (C3’’’),	 72.6	 (-CH2Ph),	 72.5	 (-CH2Ph),	 71.8	
(C4’’’),	71.6	(-CH2Ph),	71.5	(C5’),	70.6	(C4’),	64.0	(C5’’),	63.0	(C2’),	62.3	(C6’),	60.5	(C3),	







mixture	 was	 kept	 stirring	 at	 room	 temperature	 for	 16	 h.	 After	 adding	 3	 M	 sodium	
hydroxide	soln.	 (4.9	mL)	and	20%	sodium	thiosulfate	 soln.	 (4.9	mL),	 the	mixture	was	
stirred	at	room	temperature	for	1	h.	The	reaction	mixture	was	then	extracted	with	ethyl	
acetate	 and	 the	 organic	 layer	 was	 washed	 with	 water	 and	 brine,	 dried	 with	 sodium	
sulfate,	filtered	and	concentrated	under	reduced	pressure.	The	residue	was	purified	by	
flash	column	chromatography	over	silica	gel	(hexane:	ethyl	acetate	4:	1)	to	give	129	as	
colorless	 oil	 (586	 mg,	 50%).	 [α]23D 	 =	 +83.2°	 (c	 =	 0.8,	 dichloromethane).	 Rf	 (hexane:	
ethyl	acetate	2:	1)	0.66.	1H	NMR	(600	MHz,	chloroform-d)	δ	7.40	–	7.11	(m,	20H),	5.31	















107.0	 (C1’’),	 98.5	 (C1’’’),	 86.4	 (C5),	 83.8	 (C4’’),	 83.0	 (C6),	 81.7	 (C2’’),	 75.4	 (C4),	 75.3	
(-CH2Ph),	 75.1	 (C3’’),	 74.1	 (C5’’’),	 72.8	 (C3’’’),	 72.5	 (-CH2Ph),	 72.4	 (-CH2Ph),	 71.7	
(-CH2Ph),	 71.5	 (C4’’’),	 63.2	 (C5’’),	 60.5	 (C1),	 59.5	 (C3),	 57.5	 (C2’’’),	 51.1	 (C6’’’),	 18.0	
(-CH(CH3)2),	 11.9	 (-CH(CH3)2).	 ESI-HRMS:	 m/z	 calcd	 for	 C54H70N12NaO10Si	 [M+Na]+	
1097.5005,	found	1097.5008.	
1,3,2’,2’’’,6’’’-Pentadeamino-1,3,2’,2’’’,6’’’-pentaazido-6,6’,2’’,3’’’,4’’’-penta-O-benzy
l-3’,4’-dideoxy-4’-C-propyl	 paromomycin	 (133)	 Glycosyl	 donor	123	 (192	mg,	 0.46	
mmol),	glycosyl	acceptor	129	(444	mg,	0.41	mmol),	2,4,6-tri-tert-butylpyrimidine	(571	
mg,	2.3	mmol),	and	activated	4Å	molecular	sieves	(700	mg)	were	put	 in	a	 flame	dried	
flask	 and	 dry	 dichloromethane	 (7.2	mL)	was	 added	 under	 an	 argon	 atmosphere.	 The	
mixture	was	stirred	at	room	temperature	for	1	h,	and	cyclohexene	(48	μL,	0.47	mmol)	





stirred	 at	 -60	 oC	 under	 an	 argon	 atmosphere	 for	 17	 h.	 Triethylamine	 (0.6	 mL)	 was	
added	 to	 quench	 the	 reaction	 and	 the	 mixture	 was	 allowed	 to	 warm	 up	 to	 room	
temperature.	 The	 mixture	 was	 flitered	 through	 a	 Celite	 pad	 and	 washed	 with	
dichloromethane.	 The	 combined	 filtrate	 was	 washed	with	 saturated	 aqueous	 sodium	
bicarbonate	 and	 brine,	 dried	 with	 sodium	 sulfate,	 filtered	 and	 concentrated	 under	
reduced	 pressure.	 After	 purification	 by	 flash	 column	 chromatography	 over	 silica	 gel	
(hexane:	 ethyl	 acetate	 9:	 1),	 the	 resulting	 compound	 (223	 mg,)	 was	 dissolved	 in	
tetrahydrofuran	(5	mL)	and	tetrabutylammonium	fluoride	(1	M	in	tetrahydrofuran,	0.2	
mL)	 was	 added.	 After	 stirring	 at	 room	 temperature	 for	 1	 h,	 the	 mixture	 was	
















0.86	 (t,	 J	 =	 7.0	 Hz,	 3H,	 CH3).	 ESI-HRMS:	 m/z	 calcd	 for	 C61H71N15NaO12	 [M+Na]+	
1228.5304,	found	1228.5309.	
6,6’,2’’,3’’’,4’’’-Penta-O-benzyl-1,3,2’,2’’’,6’’’-penta-N-(benzyloxycarbonyl)-3’,4’-did
eoxy-4’-C-propyl	 paromomycin	 (134)	 A	 soln.	 of	 133	 (107	 mg,	 0.09	 mmol)	 in	
tetrahydrofuran	(2	mL)	was	treated	with	trimethylphosphine	(1	M	in	tetrahydrofuran,	
0.72	 mL,	 0.72	 mmol).	 After	 heating	 at	 70	 oC	 for	 1	 h	 under	 an	 argon	 atmosphere,	
deionized	water	(0.8	mL)	was	added	and	the	mixture	was	kept	stirring	at	70	oC	for	3	h.	
All	solvent	was	evaporated	under	reduced	pressure	and	the	residue	was	dissolved	in	a	
mixture	 of	 methanol/water	 (1:	 1,	 2	 mL).	 The	 mixture	 was	 stirred	 with	 potassium	
carbonate	(99	mg,	0.72	mmol)	and	N-(benzyloxycarbonyloxy)succinimide	(180	mg,	0.72	
mmol)	at	room	temperature	for	16	h,	and	then	extracted	with	ethyl	acetate.	The	organic	
layer	was	washed	with	 saturated	 aqueous	 sodium	 bicarbonate	 and	 brine,	 dried	with	
sodium	 sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 Flash	 column	
chromatography	over	silica	gel	(hexane:	ethyl	acetate	2:	1)	afforded	134	as	colorless	oil	
(117	mg,	74%).	[α]23D 	 =	+	12.3°	(c	=	1.0,	dichloromethane).	Rf	(hexane:	ethyl	acetate	1:	
1)	 0.62.	 ESI-HRMS:	 m/z	 calcd	 for	 C101H111N5NaO22	 [M+Na]+	 1769.7652,	 found	
1769.7651.	 This	 compound	 was	 employed	 in	 the	 next	 step	 without	 further	






rideoxy-5’’-azido-4’-C-propyl	 paromomycin	 (135)	 To	 a	 soln.	 of	134	 (117	mg,	 0.07	
mmol)	in	dry	dichloromethane	(2	mL)	were	added	p-toluenesulfonyl	chloride	(127	mg,	
0.7	mmol),	 triethylamine	 (0.16	mL,	 1.3	mmol)	 and	4-dimethylaminopyridine	 (0.8	mg,	
0.007mmol).	After	stirring	at	room	temperature	for	22	h,	the	mixture	was	diluted	with	
ethyl	 acetate,	 washed	 with	 saturated	 aqueous	 sodium	 bicarbonate	 and	 brine.	 The	
organic	 layer	was	dried	with	sodium	sulfate,	 filtered	and	concentrated	under	reduced	
pressure.	 The	 residue	 was	 dissolved	 in	 dimethylformamide	 (2	 mL)	 and	 stirred	 with	
sodium	 azide	 (78	 mg,	 1.2	 mmol)	 at	 70	 oC	 for	 19	 h.	 After	 cooling	 down	 to	 room	
temperature,	 the	 mixture	 was	 diluted	 with	 ethyl	 acetate,	 washed	 with	 saturated	





This	 compound	was	 employed	 in	 the	 next	 step	without	 further	 characterization.	 The	
presence	 of	 rotamers	 in	 the	 multiple	 Cbz	 groups	 rendered	 the	 NMR	 spectrum	
uninterpretable.	 	
1,3,2’,2’’’,6’’’-Pentadeamino-1,3,2’,2’’’,6’’’-pentaazido-6,6’,2’’,3’’’,4’’’-penta-O-benzy
l-3’,4’-dideoxy-4’-C-propyl-5’’-O-tosyl	 paromomycin	 (138)	Compound	133	 (92	mg,	





4-dimethylaminopyridine	 (0.9	 mg,	 0.008mmol).	 The	 reaction	 mixture	 was	 stirred	 at	
room	temperature	for	24	h,	and	then	extracted	with	ethyl	acetate.	The	organic	layer	was	
washed	with	saturated	aqueous	sodium	bicarbonate	and	brine	and	dried	with	sodium	
sulfate.	 Filtration,	 concentration	 under	 reduced	 pressure	 and	 purification	 by	 flash	
column	 chromatography	 over	 silica	 gel	 (hexane:	 ethyl	 acetate	 4:	 1)	 gave	 138	 as	 a	
colorless	oil	(83	mg,	80%).	[α]23D 	 =	+	42.8°	(c	=	0.2,	dichloromethane).	Rf	(hexane:	ethyl	

















MHz,	 chloroform-d)	 δ	 144.7	 (aromatic),	 138.5	 -	 136.9	 (aromatic),	 132.9	 (aromatic),	
129.9	-	127.5	(aromatic),	106.1	(C1’’),	99.1	(C1’’’),	95.7	(C1’),	83.8	(C6),	81.6	(C5),	81.3	
(C2’’),	 80.3	 (C4’’),	 75.7	 (C3’’),	 75.0	 (-CH2Ph),	 74.6	 (C4),	 73.7	 (-CH2Ph),	 73.3	 (-CH2Ph),	
73.2	 (C3’’’),	 73.1	 (C5’’’),	 72.5	 (-CH2Ph),	 72.2	 (C5’),	 72.0	 (-CH2Ph),	 71.9	 (-CH2Ph),	 71.2	
(C4’’’),	 70.0	 (C6’),	 69.2	 (C5’’),	 60.5	 (C3),	 60.5	 (C1),	 57.4	 (C2’’’),	 57.1	 (C2’),	 50.7	 (C6’’’),	
35.1	 (C4’),	 33.3	 (CH2CH2CH3),	 32.7	 (C2),	 27.2	 (C3’),	 21.6	 (CH3Ph),	 19.1	 (CH2CH3),	 14.3	
(CH2CH3).	 ESI-HRMS:	 m/z	 calcd	 for	 C68H77N15NaO14S	 [M+Na]+	 1382.5393,	 found	
1382.5390.	
1,3,2’,2’’’,6’’’-Pentadeamino-1,3,2’,2’’’,6’’’-pentaazido-6,6’,2’’,3’’’,4’’’-penta-O-benzy




aqueous	 sodium	 bicarbonate	 and	 brine.	 The	 organic	 layer	 was	 dried	 with	 sodium	
sulfate,	 filtered	 and	 concentrated	 under	 reduced	 pressure.	 Flash	 column	














9.1	Hz,	1H,	H4),	 3.38	–	3.27	 (m,	3H,	H6’’’,	H1,	H3),	3.26	 (t,	 J2’’’-1’’’	 =	 J2’’’-3’’’	 =	1.9	Hz,	1H,	
H2’’’),	3.21	–	3.14	(m,	3H,	H6’’’,	H2’,	H4’’’),	2.81	(t,	J	=	9.1	Hz,	1H,	H6),	2.15	(dt,	J2eq-2ax	=	
13.2	Hz,	J2eq-3	=	J2eq-1	=	4.6	Hz,	1H,	H2eq),	1.97	(dt,	J3’eq-3’ax	=	12.3	Hz,	J3’eq-4’	=	J3’eq-2’	=	4.0	
Hz,	1H,	H3’eq),	1.86	–	1.79	(m,	1H,	H4’),	1.74	(q,	 J3’ax-3’eq	=	 J3’ax-2’	=	 J3’ax-4’	=	12.3	Hz,	1H,	
H3’ax),	1.47	–	1.35	(m,	1H,	CH2CH3),	1.33	–	1.16	(m,	3H,	H2ax,	CH2CH3,	CH2CH2CH3),	1.14	
–	 1.05	 (m,	 1H,	 CH2CH2CH3),	 0.86	 (t,	 J	 =	 7.1	 Hz,	 3H,	 CH3).	 13C	 NMR	 (151	 MHz,	
chloroform-d)	 δ	 168.3	 (-CON-),	 138.4	 –	 132.3	 (aromatic),	 128.6	 –	 127.1	 (aromatic),	
106.2	 (C1’’),	 98.7	 (C1’’’),	 96.0	 (C1’),	 83.2	 (C6),	 80.9	 (C4’’),	 80.4	 (C2’’),	 79.8	 (C5),	 77.4	
(C3’’),	 75.5	 (C4),	 74.5	 (-CH2Ph),	 73.2	 (-CH2Ph),	 73.1	 (C3’’’),	 73.0	 (C5’’’),	 72.4	 (-CH2Ph),	












was	 dissolved	 in	 dry	 dichloromethane	 (2	 mL)	 and	 freshly	 prepared	 formic	 acetic	
anhydride	(0.1	mL)	was	added.	After	stirring	at	room	temperature	for	0.5	h,	the	mixture	
























3’,4’,5’’-Trideoxy-4’-C-propyl-5’’-formamido	 paromomycin	 101	 Palladium	
hydroxide	on	carbon	 (24	mg)	was	added	 into	a	 soln.	of	140	 (12	mg,	0.01	mmol)	 in	a	
mixture	of	dioxane/10%	AcOH	(2:	1,	0.6	mL).	The	mixture	was	stirred	under	a	hydrogen	
atmosphere	 (48	 psi)	 for	 7	 d,	 and	 then	 filtered	 through	 a	 Celite	 pad.	 The	 solid	 was	
washed	 with	 deionized	 water	 and	 the	 combined	 filtrate	 was	 concentrated	 under	
reduced	 pressure	 and	 purified	 by	 Sephadex	 C-25	 column	 chromatography	 (gradient	
elution	 of	 0.1%	 -	 1.0%	 ammonium	 hydroxide	 in	 deionized	 water).	 The	
















179.8	 (CH3CO2H),	 164.9	 (-CHO),	 109.8	 (C1’’),	 95.3	 (C1’’’),	 94.7	 (C1’),	 83.8	 (C5),	 79.5	
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threat	 to	 human	 health	 and	 society	 today.	 Many	 researchers	 tried	 to	 develop	 next	
generation	 of	 antibiotics	 by	 reinvesting	 the	 existing	 antibacterial	 drugs.	
Aminoglycosides	have	long	been	used	as	highly	potent	and	broad-spectrum	antibiotics	
for	 treating	 bacterial	 infections.	 But	 their	 side	 effect,	 especially	 the	 irreversible	
ototoxicity,	 and	 the	 fast-growing	resistant	problem	 limit	 their	application.	The	goal	of	
this	 research	 was	 to	 develop	 next	 generation	 of	 AGAs	 that	 are	 less	 toxic	 and	
resistance-proof	by	modifying	known	aminoglycosides.	 	
Chapter	 one	 briefly	 explains	 the	 MDR	 bacterial	 infection	 problem	 and	 its	
influence.	 Aminoglycosides	 are	 also	 well	 discussed	 in	 this	 chapter,	 including	 their	
history,	classifications,	mechanism	of	action,	toxicity	and	resistance	problems,	as	well	as	
the	recent	research	advances.	




6’-deshydroxymethyl	 paromomycin	 The	 loss	 of	 activity	 shows	 in	 the	 biological	 test	
suggested	that	the	6'-deshydroxymethyl	modification	was	not	an	effective	modification.	 	
Chapter	three	discusses	the	3’-deoxy	modification	on	different	4,5-AGAs.	A	novel	
synthetic	 method	 utilizing	 samarium	 iodide	 reduction	 to	 achieve	 3’-deoxygenation	




Chapter	 four	 describes	 the	 synthesis	 and	 biological	 test	 results	 of	 the	
3’,5’’-dideoxy-5’’-formamido	 paromomycin.	 The	 synthesis	 of	 this	 doubly	 modified	
compound	 demonstrates	 the	 wide	 application	 potency	 of	 the	 samarium	 iodide	
reduction	 for	 3’-deoxy	modification.	 The	 biological	 experiment	 results	 show	 that	 the	
doubly	modified	compound	has	good	antibacterial	activity	even	in	the	presence	of	some	
common	AMEs.	 	
Chapter	 five	 discussed	 the	 synthesis	 and	 biological	 evaluation	 of	 a	 triply	
modified	 paromomycin	 derivative.	 The	 combination	 of	 3’-deoxy,	 4’-deoxy-4’-C-propyl	
and	5’’-deoxy-5’’-formamido	modification	into	paromomycin	leads	to	unexpected	loss	of	
antiribosomal	and	antibacterial	activity.	 	
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